

AP20 Rec'd PCT/PTO 29 JUN 2006

**RECOMBINANT VACCINE AGAINST JAPANESE ENCEPHALITIS VIRUS
(JEV) INFECTION AND A METHOD THEREOF****Field of the invention**

- 5 The present invention relates to a method of preparing a novel recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection. Also, it relates to a method of immunization and to the vaccine *per se*.

Background and prior art references of the invention

- 10 Japanese encephalitis virus (JEV) is a member of the *flaviviridae* family of animal viruses that consists of several viruses of immense medical significance such as those causing dengue and yellow fever. JEV, transmitted to human beings by mosquitoes, is responsible for an acute infection of the central nervous system resulting in encephalitis. The virus is active over a vast geographic area covering India, China, Japan and virtually all of the South-East Asia. Approximately 3 billion people live in
- 15 JEV endemic area and up to 50,000 cases of JEV infection are reported every year, of which, about 10,000 cases result in fatality and a high proportion of survivors end up having serious neurological and psychiatric sequel (45). A mouse brain-grown, formalin-inactivated JEV vaccine is available internationally. However, this vaccine has limitations in terms of its high cost of production, lack of long-term immunity and
- 20 risk of allergic reaction due to the presence of the murine encephalogenic basic proteins or gelatin stabilizer (1, 33, 38, 39). There is, thus, an urgent need to develop an improved vaccine against JEV and several potential vaccines are currently being investigated in various laboratories (16).

- JEV contains a single-stranded, plus-sense RNA genome of ~11 Kb. It consists of a
- 25 single open reading frame that codes for a large polyprotein of 3432 amino acids which is co- and post-translationally cleaved into three structural (capsid, C; pre-membrane, prM; and envelope, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (5, 44). In flaviviruses, E protein is involved in a number of important functions related to virus infection such as receptor binding and membrane
- 30 fusion (26). Antibodies to the E protein were shown to neutralize virus activity *in vitro* as well as *in vivo* since passive administration of monoclonal antibodies to the E protein protected mice with JEV infection (17). Furthermore, sub-viral particles consisting of only the prM and the E proteins were highly effective in generating protective immune response in mice against JEV (18, 25). Chen *et al.* (7) examined the potential of

various JEV structural and non-structural proteins for vaccine development. They concluded that the E protein was the single most important protein capable of inducing protective immunity against JEV. Accordingly, several plasmid vectors have been described synthesizing different forms of JEV E protein with or without prM protein and these provided protection of varying degree in mice against Japanese encephalitis (2, 6, 15, 20).

In recent years, adenoviruses have shown great promise as vectors for recombinant vaccine development (3, 4, 8, 13, 35, 41, 42, 49). Besides being safe, these viruses have been shown to induce effective humoral and cellular immune responses in experimental animals when delivered orally, intra-muscular (IM), intra-peritoneal or intra-nasal (3, 21, 24, 40, 41, 50). In the present invention, we constructed RAdEa expressing the prM and the full length JEV E protein since it is known to induce neutralizing immune response. However, adenovirus recombinant (RAdEa) synthesizing the full-length protein (Ea) did not grow well. Besides it induced poor immune response and very little JEV neutralizing antibodies. The full-length E protein is membrane anchored and removing the anchor signal from it is likely to make it soluble and perhaps more immunogenic.

On this premise, we truncated the Ea protein to remove 102-amino acid hydrophobic sequence from the C-terminus of the protein to generate a 398-amino acid Es protein. Recombinant adenovirus RAdEs synthesizing JEV prM and Es was found to grow very well in cultured cells and synthesize JEV E protein that was secreted into the medium. So, the removal of 102-amino acid hydrophobic sequence from the C-terminus of the protein played a critical role in smooth culturing of the recombinant. Even the inventors were pleasantly surprised with this effect.

Further, this recombinant adenovirus, synthesizing a novel form of JEV E protein that was secretory as opposed to the anchored protein in the normal course, was highly immunogenic in mice. RAdEs induced high titers of JEV neutralizing antibodies and protected the immunized mice against lethal JEV challenge demonstrating its potential use as a vaccine against JEV infection. The highly immunogenic effect of the recombinant helped achieve the desired results, which were long awaited by the scientific community.

The infection caused by JEV is fatal in nature and absence of long-term immunity had added to the problem. The allergic reactions to the known vaccine had further

compounded the problem. However, administration of the vaccine of instant invention is been found to be absolutely safe and free from adverse effects.

Objects of the invention

The main object of the present invention is to develop a recombinant adenovirus (RAdEs) vaccine against JEV infection.

Another main object of the present invention is to develop an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection.

Yet another object of the present invention is to develop a plasmid pAdEs of SEQ ID No. 1.

Still another object of the present invention is to develop a method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection.

Summary of the invention

The present invention relates to development of a novel recombinant adenovirus (RAdEs) vaccine against Japanese encephalitis virus (JEV) infection.

Detailed description of the invention

Accordingly, the present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against JEV infection; an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection; also, a plasmid pAdEs of SEQ ID No. 1; and lastly, a method of preparing the recombinant adenovirus (RAdEs) vaccine.

In the main embodiment of the present invention, it relates to a method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection, wherein the said vaccine produces secretory envelop protein of JEV, said method comprising steps of:

- digesting plasmid pMEs with restriction enzymes *Kpn* I and *Bam* HI to obtain cDNA encoding JEV proteins prM and Es,
- ligating the cDNA to adenovirus shuttle plasmid pShuttle digested with restriction enzymes *Kpn* I and *Hind* III at the *Kpn* I end,
- filling nucleotides at the free *Bam* HI and *Hind* III ends with T4 DNA polymerase to create blunt ends,
- ligating the blunt ends together to yield shuttle plasmid pSEs with JEV cDNA encoding the proteins prM and Es,

- digesting the shuttle plasmid pSEs with restriction enzymes *I-Ceu* I and *Pl-Sce* I to obtain expression cassette containing the JEV cDNA together with the CMV promoter/enhancer and BGH polyadenylation signal,
- 5 • ligating the digested shuttle plasmid with *I-Ceu* I and *Pl-Sce* I digested adenovirus plasmid pAdeno-X to generate plasmid pAdEs containing the Es expression cassette,
- digesting the plasmid pAdEs with *Pac* I,
- transfecting the monolayers of HEK 293 cells with digested plasmid
10 pAdEs for about one week, and
- obtaining the recombinant virus RAdEs vaccine.

In another embodiment of the present invention, the transfection is at about 37°C temperature.

15 In yet another embodiment of the present invention, the secretory proteins are under the control of human CMV IE promoter/enhancer.

In another main embodiment of the present invention, the invention relates to a recombinant adenovirus (RAdEs) vaccine.

In yet another embodiment of the present invention, the vaccine produces secretory envelop protein (Es) of JEV.

20 In still another embodiment of the present invention, the vaccine protects against Japanese encephalitis virus (JEV) infection.

In still another embodiment of the present invention, the vaccine is effective by intra-muscular route of administration.

25 In another main embodiment of the present invention, the invention relates to a plasmid pAdEs of SEQ ID No. 1.

30 In another main embodiment of the present invention, the invention relates to an effective and superior method of immunizing a subject in need thereof, to Japanese encephalitis virus (JEV) infection, said method comprising the step of administering a pharmaceutically effective amount of recombinant virus RAdEs vaccine optionally along with additive(s) to the subject intra-muscularly.

In yet another embodiment of the present invention, the method shows 100% efficacy.

In still another embodiment of the present invention, the method helps protect subject against Japanese encephalitis.

In still another embodiment of the present invention, the subject is animal.

In still another embodiment of the present invention, the subject is a human being.

In still another embodiment of the present invention, the immunization activates both humoral and cell-mediated immune responses.

5 In still another embodiment of the present invention, the humoral response to the vaccine is antibody IgG1 type.

In still another embodiment of the present invention, the method leads to high amount of IFN-gamma secretion.

10 In still another embodiment of the present invention, the immunization leads to IL-5 secretion at moderate levels.

In still another embodiment of the present invention, increased amounts of RAdEs lead to higher immune response.

In still another embodiment of the present invention, the method is more effective than the commercially available vaccine.

15 Replication-defective recombinant adenoviruses (RAdEs) were constructed that synthesized the pre-Membrane (prM) and envelope (E) proteins of Japanese encephalitis virus (JEV). Recombinant virus RAdEa synthesized Ea, the membrane-anchored form of the E protein, and RAdEs synthesized Es, the secretory E protein. RAdEa replicated poorly in human embryonic kidney (HEK) 293A cells and 88-folds
20 lower titers of the virus were obtained compared to RAdEs. RAdEa also synthesized lower amounts of E protein in HEK 293A cells as judged by radioimmunoprecipitation and immunofluorescence studies.

Mice were immunized intra-muscular (IM) and orally with RAdEs. Oral route of virus delivery induced low titers of anti-JEV antibodies that had only little JEV neutralizing
25 activity. IM immunizations with both RAdEa and RAdEs resulted in high titers of anti-JEV antibodies. Interestingly, RAdEa induced very low titers of JEV neutralizing antibodies whereas RAdEs inoculation resulted in high titers of JEV neutralizing antibodies. Splenocytes from mice immunized IM with RAdEs secreted large amounts of interferon- γ and moderate amounts of interleukin-5. These splenocytes also showed
30 cytotoxic activity against JEV-infected cells. Mice immunized IM with RAdEs showed complete protection against the lethal dose of JEV given intra-cerebral.

Brief description of the accompanying drawings:

Fig. 1 shows Growth of RAdS in HEK 293A cells. Monolayers of HEK 293A cells in 35-mm tissue culture dishes were infected with RAdS at a multiplicity of infection (MOI) of 1 and incubated at 37 °C in 3 ml culture medium. At 6 hr interval the cell monolayers were lysed in the culture medium by three cycles of freeze-thawing. The cell lysate was centrifuged to remove the debris and the supernatant assayed for adenovirus titers on HEK 293A cells. Shown in the figure are virus titers at various time points.

Fig. 2 shows Synthesis of JEV proteins in HEK 293A cells infected with RAdS. HEK 293A cells were infected with JEV or RAdS at a MOI of 1. Cells were labelled 24 hr later by growth in medium containing ³⁵S-methionine and ³⁵S-cystine. After labeling, culture supernatant (CS) and cells were harvested separately. Cells were washed with PBS before the cell lysate (CL) was made. CLs and CSs were used for immunoprecipitation of JEV proteins with mouse anti-JEV serum. The proteins were separated on a 12% SDS-polyacrylamide gel and autoradiographed. Lanes containing proteins precipitated from JEV-, RAdEa- or RAdEs-infected or uninfected cells have been identified. Position of JEV proteins has been indicated at the left. Ea, Es and prM proteins synthesized by RAdS have been indicated. The values on the right are molecular size markers in kDa.

Fig. 3 shows Immunofluorescent staining of virus-infected cells. HEK 293A cells were infected with RAdS or JEV at a MOI of 1. The cells were fixed and permeabilized 24 hr later and stained with mouse anti-JEV serum followed by FITC-conjugated goat anti-mouse-IgG. They were then observed under a microscope using ultra-violet light. Panel A, RAdEa-infected cells; panel B, RAdEs-infected cells; panel C, JEV-infected cells and panel D, uninfected cells.

Fig. 4 shows Antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdS) and the routes of inoculation have been indicated below the figure. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer (pH 8.9). The primary immunization was followed by booster doses that were given 21 and 36 days later. Mice were bled at day 20, 28 and 44 post-immunization and sera stored at -70 °C. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point anti-JEV antibody titers by ELISA.

Shown above are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent titers on day 20, the gray bars represent titers on day 28 and black bars show titers on day 44 post-immunization.

Fig. 5 shows Isotype analysis of anti-JEV antibody produced by immunized mice.

5 BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAds) and the routes of inoculation have been indicated below the figure. The primary immunization was followed by booster doses given 21 and 36 days later. Mice sera obtained on day 44 post-immunization were assayed for the end-point ELISA titers of anti-JEV IgG1 and
10 IgG2a antibodies. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point titers. The ELISA titer was recorded as zero if the 1:25 dilution of sample was negative in ELISA. Shown in the figure are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent IgG1 titers and the gray bars represent IgG2a titers. The inverted triangle indicates zero mean
15 titer.

Fig. 6 shows JEV neutralizing antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation. The dosages of the immunogens and the route of inoculation have been indicated at the top of the figure. The primary immunization was followed by booster doses given 21 and
20 36 days later. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer. Mice were bled on day 44 post-immunization and sera stored at -70 °C. Serial two-fold dilutions of sera (starting at 1:10) were assayed for end-point JEV neutralization titers by plaque reduction neutralization assays. Shown in the figure are mean JEV neutralization titers of serum samples from immunized mice.

25 Fig. 7 shows Cytokine production by splenocytes from immunized mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation as indicated at the top of the figure. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were
30 cultured in presence of JEV. Culture supernatants were collected each day and stored at -70 °C. These were then assayed for IFN- γ , IL-4 and IL-5. Shown in the figure are the levels of IFN- γ and IL-5 in splenocyte cultures on various days after incubation with JEV. The days are numbered at the bottom of the panel.

Fig. 8 shows CTL activity in immunized mice. BALB/c mice were immunized with RAdEa or RAdEs by IM route of inoculation. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were cultured in presence of JEV for the generation of effector cells. Shown in the figure is the CTL activity of splenocytes at various ratios of effector cells to target cells (E : T) which are indicated at the bottom of the panels.

Fig. 9 shows Mice survival after challenge. Groups of 6-8 BALB/c mice were immunized with various dosages of RAdEa and RAdEs through IM or oral route. These mice received two booster doses of the immunogen on day 22 and 36 post-immunization. Mice were challenged on day 44 post-immunization with 100 LD₅₀ (50%-lethal dose) of JEV given intra-cerebrally. Mice were observed for mortality for the next three weeks. Shown above is the percentage of surviving mice at a given time point. Immunogen dose and route of inoculation have been indicated. *indicates oral delivery of RAdEs along with the bicarbonate buffer.

The invention is further elaborated with the help of experimental data, as presented below in the form of examples. However, the examples should not be construed to limit the scope of the invention

Example – 1

JEV and cells: The GP78 strain of JEV was used in these studies (44). The virus was grown in neonatal mouse brain. The brain from infected mice was homogenized as a 10% suspension in Eagle's minimal essential medium (EMEM). The suspension was centrifuged and filtered through 0.22 µm sterile filters. The virus was stored at -70 °C in aliquots. Virus titration was carried out by plaque assay on porcine stable kidney (PS) monolayers as described previously (43). Adenovirus was grown in human embryonic kidney (HEK) 293A cells (Quantum Biotechnologies Inc.) cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS).

Example – 2

Construction of recombinant adenoviruses: Recombinant adenoviruses were constructed using the Adeno-X expression system (BD Biosciences) that utilized a ligation-based strategy for producing recombinant virus. Using this system a mammalian expression cassette containing the cDNA encoding JEV E protein was

incorporated into a replication incompetent (E1/ E3) human adenovirus type 5 (Ad5) genome. Two recombinant adenoviruses (RAd)s were made; RAdEa, synthesizing JEV prM and the membrane-anchored E protein, and RAdEs, synthesizing prM and the secretory E protein. Plasmids pMEa and pMEs that contained the cDNAs encoding JEV prM and the membrane-anchored (Ea) or secretory E protein (Es), respectively have been described previously (15). Plasmid pMEa was modified by site-directed mutagenesis to contain an *Afl* II restriction site down-stream of the 3'-end of the JEV cDNA past the *Bam* HI site. The JEV cDNA encoding the prM and Ea proteins was excised from the mutated pMEa as a *Kpn* I - *Afl* II fragment and cloned at these sites in the adenovirus shuttle plasmid pShuttle (BD Biosciences) under the control of human cytomegalovirus (CMV) immediate early (IE) promoter/enhancer to yield plasmid pSEa. The shuttle plasmid pSEa contained the bovine growth hormone (BGH) polyadenylation signal downstream of the cloned JEV cDNA. The cDNA encoding prM and Es sequence was obtained by digesting pMEs with *Kpn* I and *Bam* HI. This cDNA fragment was ligated to the adenovirus shuttle plasmid, pShuttle, digested with *Kpn* I and *Hind* III at the *Kpn* I end. The free *Bam* HI and *Hind* III ends were nucleotide filled with T4 DNA polymerase and the blunt ends so created were ligated together to yield plasmid pSEs where JEV cDNA encoding prM and Es was under the control of human CMV IE promoter/enhancer. The shuttle plasmid pSEs contained the BGH polyadenylation signal downstream of the cloned cDNA. The junctions of the shuttle plasmid and the cDNA insert were sequenced to confirm the presence of the cDNA in correct frame. The plasmids pSEa and pSEs were digested with *I-Ceu* I and *Pf-Sce* I to obtain the expression cassettes containing the JEV cDNA together with CMV promoter/enhancer and BGH polyadenylation signal. These were then ligated with *I-Ceu* I and *Pf-Sce* I digested adenovirus plasmid pAdeno-X (BD Biosciences) to generate plasmids pAdEa and pAdEs containing the Ea and Es expression cassettes, respectively. Monolayers of HEK 293A cells were transfected with *Pac* I digested pAdEa and pAdEs using Effectene (Qiagen) and incubated for a week at 37 °C. By this time, RAd plaques had begun to show. The cell monolayers were harvested in culture supernatant, frozen-thawed thrice and centrifuged to obtain the released crude recombinant virus that was amplified once in HEK 293A cells and subjected to 2 rounds of plaque purification to obtain recombinant viruses RAdEa and RAdEs.

Example – 3

Radioimmunoprecipitation: Synthesis of JEV proteins by RAdEa and RAdEs was studied by infection of HEK 293A cells followed by radiolabelling and immunoprecipitation. Briefly, monolayers of HEK 293A cells were infected with virus at a multiplicity of infection (MOI) of 1 and incubated at 37 °C. After 24 hr, the cell monolayer was radiolabelled by growing in presence of 100 µCi of Easytag™ EXpre³⁵S³⁵S protein labeling mix (NEN) for 4 hr. The culture supernatant was harvested and stored at -70 °C. The monolayers were harvested in 500 µl of radioimmunoprecipitation assay buffer (10 mM Tris-HCl pH 8.0, 140 mM NaCl, 5 mM Iodoacetamide, 0.5% Triton X-100, 1% Sodium dodecyl sulphate (SDS), 1% Sodium deoxycholate, 2 mM Phenylmethylsulfonyl fluoride). Immunoprecipitation was carried out using mouse anti-JEV serum (ATCC) and Protein A Sepharose beads (Amersham). Immunoprecipitated proteins were electrophoresed on a 12% SDS-polyacrylamide gel that was dried before exposing to X-ray film for autoradiography.

Example – 4

Immunofluorescent staining: Monolayers of HEK 293A cells were infected with RAdEa, RAdEs or JEV at a MOI of 1. The cells were fixed the next day with 2% Paraformaldehyde and permeabilized with 0.1% Triton-X 100. These cells were then stained by incubation with mouse anti-JEV serum (ATCC) followed by anti-mouse IgG-FITC conjugate (Dako) and observed under a microscope using ultra-violet light.

Example – 5

Mice immunization and challenge experiments: All immunizations were carried out on 4-5-week-old inbred BALB/c mice. Each immunization group consisted of 6-8 mice. For IM immunizations, mice were injected in the hind legs with different amounts of RAds diluted in 100 µl phosphate-buffered saline (PBS) using a 30G needle. Another group of mice was immunized with the mouse brain-derived, formalin-inactivated JEV vaccine manufactured by the Central Research Institute, Kasauli (India). Each mouse was given an IM injection of 100 µl of the vaccine that was 1/10th of the recommended adult human dose. For oral immunizations, water was withdrawn from the mice cages for 6-8 hr and then 200-400 µl virus diluted in PBS or 100 mM Sodium bicarbonate buffer (ph 8.9) was administered per oral using a mouse-feeding needle that had a small balloon at the point of the delivery. Two booster doses, given 3 and 5 weeks after the primary immunization, contained the same amount of

immunogen as the primary dose. At 44 days post-immunization, mice were challenged with intra-cerebral inoculation of the lethal dose of JEV. These mice were observed for mortality for the next 3 weeks.

Example – 6

5 **Antibody assays:** Titers of anti-JEV antibodies were assayed using an enzyme-linked immunosorbent assay (ELISA). An ELISA plate was coated with C6/36 cell-grown JEV overnight at 4 °C in 0.2 M Sodium carbonate buffer, pH 9.6 (36). The plate was washed with PBS containing 0.1% Tween-20 (PBS-T) thrice and the wells were blocked with 1% Lactogen in PBS-T at 37 °C for 2 hr. The plate was again washed
10 with PBS-T thrice and incubated with 100 µl diluted mice sera per well at 37 °C for 1 hr. Serial two-fold dilutions of sera were assayed starting at a dilution of 1:25. The plate was then washed thrice with PBS-T and 100-µl anti-mouse antibody conjugated to horse radish peroxidase (HRP) (Dako), diluted 1:2000, was added per well, followed by incubation at 37 °C for 1 hr. The antibody-conjugate was removed by washing the
15 plate thrice with PBS-T. The plate was then incubated in dark with 100 µl per well of the substrate o-Phenylenediamine dihydrochloride (0.5 mg/ml) prepared in citrate buffer (1% Citric acid and 1.46% Disodium hydrogen phosphate) at room temperature for 10 min. The reaction was stopped by adding 50 µl of 5 N Sulfuric acid. The absorbance was read at 492 nm in an ELISA plate reader (Spectramax). The reciprocal
20 of the highest serum dilution giving an optical density at least twice that given by the reagent blanks was taken as the ELISA end-point.

The antibody isotyping ELISAs were carried out in a similar fashion, except that in place of anti-mouse IgG-HRP conjugate, anti-mouse IgG1-HRP or the IgG2a-HRP conjugate (Pharmingen) was added. This was followed by the incubation with the
25 substrate and color development as above.

Example – 7

Plaque reduction neutralization assay: Two fold serial dilutions of sera from the immunized mice (starting from 1:10) were prepared in EMEM containing 5% FCS and antibiotics. Diluted sera were incubated at 56 °C for 30 min to inactivate the
30 complement. The serum sample (100 µl) was then mixed with equal volume of JEV culture supernatant containing 100 plaque-forming units (PFU) of the virus. The virus-antibody mixture was incubated at 37 °C for 1 hr before adding to a 35-mm dish containing ~70% confluent monolayer of PS cells. The plaque assay was carried out as

described. (43). Percent neutralization was calculated by counting the number of plaques in the presence and the absence of the mouse serum. All assays were done in duplicates. Reciprocal of the highest serum dilution giving 50% neutralization was taken as the JEV neutralization titer.

5 **Example – 8**

Cytokine ELISA: Spleen cell suspensions were prepared in RPMI 1640 supplemented with 10% FCS and 6×10^7 splenocytes were incubated with 3×10^7 PFU of JEV or *E. coli*-synthesized JEV E protein (10 μ g/ml) in a 35-mm dish at 37 °C. Aliquots of culture supernatant were removed every day for the next 4 days and stored at -70 °C.

10 Interleukin (IL)-4, IL-5 and interferon (IFN)- γ were assayed using BD OptEIA kits (BD Biosciences) and as per the assay protocols.

Example – 9

Cytotoxic T lymphocyte (CTL) assay: Standard ^{51}Cr -release method as described previously (15) was used for the CTL assays with some modifications. Briefly, for
15 preparation of the responder cells, 3×10^7 splenocytes were incubated for 4 days with 3×10^7 PFU of JEV in a 35-mm dish in RPMI 1640 medium supplemented with antibiotics, 0.5 mM β -Mercaptoethanol, 0.32 mg/ml L-Glutamine, 0.1 mg/ml non-essential amino acids, 0.12 mg/ml Sodium pyruvate and 5% FCS at 37 °C. The cells thus generated were referred to as the effector cells. Virus-infected target cells were
20 prepared by infecting P388D1 cells with JEV for 48 hr at a MOI of 1 followed by incubation with 100 μCi of $\text{Na}_2^{51}\text{CrO}_4$ (NEN) and subsequent washings to remove free ^{51}Cr .

For carrying out the CTL assay, various numbers of effector cells were incubated at 37°C for 6 hr with 2×10^4 ^{51}Cr -labelled virus-infected cells by briefly centrifuging them
25 at 100 g for 4 min in a 96-well round bottom plate. At the end of the incubation period, 100 μl of cell-free supernatant was removed and the ^{51}Cr release was counted using a gamma counter (LKB). Triplicate estimations were done in all the assays and the percentage lysis was calculated using the following formula. Percent lysis = [(cpm released in the presence of effector cells – cpm released due to spontaneous leakage)/(total cpm released by 0.2% Triton X-100 lysis – cpm released due to
30 spontaneous leakage)] x 100.

Statistical analysis: The statistical significance of different findings between mouse groups was determined by Student's *t* test. $P \leq 0.05$ was considered to be significant.

Example – 10

Replication of RAds and synthesis of JEV proteins: The JEV E protein is 500 amino acids long membrane-anchored protein. We have earlier shown that deletion of the C-terminal 102 amino acids of JEV E protein leads to efficient secretion of the truncated protein into the cell surroundings (15). We had also shown that quality of immune responses in mice induced by the secretory E protein were different from those induced by the membrane-anchored E protein (15). Besides, vaccinia recombinants expressing the secretory E protein of Japanese encephalitis or Dengue viruses devoid of the membrane anchor sequence were found to be highly immunogenic in mice (14, 27, 37). We, therefore, constructed two recombinants, RAdEa synthesizing prM and Ea (full-length membrane-anchored JEV E protein) and RAdEs synthesizing prM and Es (398 amino acid secretory E protein). The JEV prM was included in our constructs as its co-synthesis was necessary for correct processing and folding of the E protein (18, 25). The presence of appropriate JEV cDNA in genomes of RAds was established by polymerase chain reaction using JEV genome sequence-specific oligonucleotide primers.

Replication of RAds was studied in HEK 293A cells infected at a MOI of 1. Figure 1 shows that a major burst in viral titers was observed both for RAdEa and RAdEs between 18 and 24 hr post-infection (PI) after which there was only a marginal increase in titers. RAdEs titer was ~40-fold higher than that of RAdEa at 24 hr PI. Following the virus replication, the cytopathic effects were first visible at 30 hr PI for both RAdEa and RAdEs. The cytopathic effects had become highly pronounced by 42 hr PI when almost 80% cells had come off the surface of the tissue culture plates. At this time point titer of RAdEs was 1.2×10^7 PFU/ml, which was 88-times higher than that of RAdEa. These results showed that compared to RAdEs, RAdEa replicated poorly in HEK 293A cells. We studied four independent isolates of RAdEa and found all them to be slow growers.

The synthesis of JEV proteins by RAds was studied in HEK 293A cells that were infected with different viruses followed by radiolabelling and immunoprecipitation of JEV proteins using mouse anti-JEV serum. Figure 2 shows that RAdEa-infected cell lysate had 2 proteins of apparent molecular masses of 51 and 23 kDa that corresponded with JEV E and prM proteins. None of these proteins were detectable in the culture supernatant of the infected cells. The RAdEs-infected cell lysate showed the synthesis

of Es and prM proteins of apparent molecular masses of 45 and 23 kDa, respectively. The culture supernatant from the RAdEs-infected cells had a significant amount of Es, indicating that the E protein synthesized by RAdEs was secretory.

5 Use of increased amounts of anti-JEV antibody and Protein A Sepharose in immunoprecipitations did not result in precipitation of enhanced amounts of E protein indicating that the amounts of these reagents used were not limiting. Scanning of the autoradiograph with optically-enhanced densitometer using 'Diversity One' software (version 1.6, PDI, New York) followed by calculations based on the volumes of the lysate or the supernatant loaded on the gel, suggested that the secretory E protein
10 present in the culture supernatant constituted about 76% of the total E protein synthesized by RAdEs-infected cells. Furthermore, levels of total Es protein synthesis were around 20-fold higher than the levels of Ea protein. Immunofluorescent staining of RAdEa- and RAdEs-infected HEK 293A cells further confirmed that levels of Ea protein were significantly lower than that of the Es protein (Figure 3). The lower levels
15 of Ea synthesis may be related to the poor growth of RAdEa in HEK 293A cells.

We found that RAdEa synthesizing the membrane-anchored E protein grew slowly and achieved 88-fold lower titers in HEK 293A cells when compared with RAdEs synthesizing the secretory E protein. Infection of HEK 293A cells with the recombinants followed by radioimmunoprecipitation of JEV proteins showed that
20 RAdEa synthesized lower amounts of JEV E protein. This was corroborated by the low levels of immunofluorescence on RAdEa-infected HEK 293A cells when compared with RAdEs-infected cells. HEK 293A cells support replication of E1-deleted RAdEs reported in this work as these cells contain Ad5 E1 transcription unit permanently integrated in them. In other mammalian cells these RAdEs are unable to replicate for the
25 want of the E1 sequences. However, expression of the foreign gene does take place, which is under the independent control of the CMV IE promoter. We have studied expression of JEV E protein by RAdEs in PS cells by immunofluorescence and radioimmunoprecipitation. No significant differences were found in the levels of E protein synthesis in PS cells infected with RAdEa or RAdEs at a MOI of 1.

30 The adenovirus vector used in our studies had deletions in both the E1 and E3 transcription units that allow packaging of up to 8 Kb foreign DNA in the recombinant virus. The size of JEV expression cassette inserted in RAdEa was ~3.3 Kb which was well within the packaging limits of the recombinant virus. The reason for lower titers of

RAdEa in HEK 293A cells is, thus, not clear. Previously, we found no differences in the levels of expression of membrane-anchored or secretory E protein of JEV when HEK 293A cells were transfected with expression plasmids containing the Ea or Es genes under CMV IE promoter (15). This observation together with our results in the PS cells on E protein synthesis indicates that lower levels of E protein synthesis by RAdEa in HEK 293A cells are related to the low levels of its replication.

Example – 11

Anti-JEV antibody response in mice immunized with RAdS: Groups of BALB/c mice were immunized with RAdEa or RAdEs delivered orally or IM. The antibody response of these mice was compared with those immunized with formalin-inactivated commercial JEV vaccine. Serum samples collected from mice at various time points were assayed for anti-JEV end-point ELISA titers. Figure 4 shows that anti-JEV antibodies were detectable in all immunization groups on day 20 post-immunization and these titers increased further on days 28 and 44 post-immunization following the booster doses. Compared to IM immunization, antibody titers were drastically low in mice immunized orally with RAdS. For example, compared to oral immunization, 1×10^8 PFU of RAdEs given IM induced ~60-fold higher antibody response on day 44. For both the oral as well as IM immunizations, higher antibody titers were obtained when higher doses of RAd were used. No significant differences were seen in day 44 anti-JEV antibody titers of mice immunized IM with 7.5×10^5 PFU of RAdEa or RAdEs. IM immunizations with RAdS induced significantly higher antibody titers than those induced by IM inoculation of the vaccine. Thus, the lower dose of RAdEa and RAdEs (7.5×10^5 PFU) gave ~ 60-fold higher antibody titers after the second booster when compared with the titers obtained with the vaccine. At the higher dose of 1×10^8 PFU, RAdEs induced ~250-fold higher titers than the vaccine on day 44.

Some investigators have carried out oral immunization of mice with RAdS using Sodium bicarbonate buffer to neutralize the acid pH of the stomach (11, 40, 47). However, there are others who have carried out oral immunization of mice with RAdS without the use of any buffer (3, 9, 42, 48). We have compared the immunogenicity in mice of RAdEs given orally (1×10^8 PFU) with or without the bicarbonate buffer. Figure 4 shows that no advantage was offered by the use of bicarbonate buffer during oral immunization with RAdEs. In fact, no effect of booster doses was seen when RAdEs was delivered orally using bicarbonate buffer and antibody titers on day 44

post-immunization were lower than in those mice that received the virus without bicarbonate buffer.

Example - 12

Isotype analyses of anti-JEV antibody produced by immunized mice: In order to
5 analyze the quality of immune responses generated by the RAds, end-point titers of
anti-JEV IgG1 and IgG2a antibodies were determined by ELISA. Figure 5 shows that
at lower dose of RAds given orally (3×10^6 PFU) titers of anti-JEV IgG1 and IgG2a
antibodies were below 25. When a higher dose of RAdEs (1×10^8 PFU) was given
orally, the majority of antibodies were of IgG1 type; the ratio of IgG1/IgG2a titers in
10 this case was 6.48 indicating a Th2 type of immune response. When RAds were
delivered through IM route, the anti-JEV antibody response was almost exclusively of
IgG1 type. In case of mice immunized IM with RAdEa (7.5×10^5 PFU), IgG1/IgG2a
titer ratio was 68 and it was 64 in the case of RAdEs (7.5×10^5 PFU)-immunized mice.
At higher dose of 1×10^8 PFU, RAdEs again induced predominantly IgG1 type of anti-
15 JEV antibodies; the ratio of IgG1/IgG2a titers in this case was 25. These results
indicated that RAdEa and RAdEs induced an almost exclusive Th2 kind of immune
response in mice when delivered IM. The IM immunization of mice with the vaccine
also induced IgG1 dominated antibody response indicating a Th2 type immune
response.

Example - 13

JEV neutralizing antibody response in mice immunized with Rads: Titers of JEV
neutralizing antibodies were determined in serum samples obtained from the
immunized mice at day 44 post-immunization. Figure 6 shows that oral route of
immunization induced very low JEV neutralizing antibodies. Similar to ELISA titers,
25 the JEV neutralizing antibody titers were lower in mice immunized orally with RAdEs
plus the bicarbonate buffer compared to titers in those mice immunized with RAdEs
without the bicarbonate buffer, although the difference was statistically insignificant.
Compared to RAdEa, RAdEs given IM induced higher JEV neutralizing titers and these
were enhanced further when higher dose of virus was used for immunization. IM
30 immunization with RAdEs induced significantly higher JEV neutralizing antibody titers
than those induced by the vaccine.

Example – 14

Cytokine secretion by splenocytes from immunized mice: Splenocytes prepared from the immunized mice were cultured in presence of JEV and synthesis of IFN- γ , IL-4 and IL-5 was studied on each day for the next 4 days. Figure 7 shows that splenocytes from mice immunize with RAdEa or RAdEs by IM route secreted large amounts of IFN- γ . Splenocytes from mice immunized with the recombinant viruses through oral route made only small amounts of IFN- γ . Similarly, mice immunized with the vaccine made only small amounts of IFN- γ . Splenocytes from IM-immunized mice also made moderate amounts of IL-5 which was almost absent in the case of orally immunized mice or mice immunized with the vaccine. IL-4 was not detectable in any of the cases; the detection limit of IL-4 ELISA was 7.8 pg/ml. Similar pattern of cytokine secretion was observed when splenocytes were cultured in presence of JEV E protein

Example – 15

CTL activity in immunized mice: To study the generation of memory CTLs, splenocytes from immunized mice were stimulated *in vitro* with JEV and examined for cytotoxic activity against cells infected with JEV. Figure 8 shows the results of CTL assays at various effector to target cell ratios. Thus, mice immunized with RAdEa or RAdEs through IM route showed significant CTL activity. No CTL activity was detectable in mice immunized with RAdEa or RAdEs through oral route. Similarly, unimmunized and Ad5-immunized mice or those immunized with the vaccine showed no CTL activity.

Example – 16

Mice challenge studies: Mice immunized with RAds were challenged at day 44 post-immunization by intra-cerebral inoculation of a lethal dose (100 LD₅₀) of JEV. These mice were observed for mortality for 3 weeks after the challenge. All mice immunized with 7.5×10^5 or 1×10^8 PFU of RAdEs given IM survived the challenge while none of the unimmunized mice survived. Furthermore, none of the mice immunized IM or orally with 1×10^8 PFU of E1/ E3 Ad5 survived the challenge. About 50-60% protection was seen in mice immunized with 1×10^8 PFU of RAdEs given orally. The level of protection was lower (30%) when mice were immunized orally with lower doses of RAdEs (3×10^5 PFU). The level of protection afforded by RAdEa immunization was very low; about 40% mice survived from those immunized with

7.5x10⁵ PFU given IM and only about 20% mice survived from the group immunized with 3x10⁶ PFU given orally. In a separate experiment, 15 mice were immunized with 1x10⁸ PFU of RAdEs and given 2 booster doses on day 21 and 35. When challenged on day 44 post-immunization with 1000 LD₅₀ of JEV, given intra-cerebral, 100% of the immunized mice survived.

The flavivirus E protein has been the antigen of choice for vaccine development using modern methods of vaccinology such as the DNA vaccination or the use of recombinant virus for antigen delivery (10, 12, 16, 28-31). This has been so because E protein plays an important role in a number of processes, including viral attachment, membrane fusion and entry into the host cell (26). Besides, flavivirus E protein induces virus-neutralizing antibodies and CTLs (14, 14, 15, 22, 23, 34). It has been shown that protection against JEV is mainly antibody dependent, and virus-neutralizing antibodies alone are sufficient to impart protection (19, 32). This was also implied from our previous observation that the formalin-inactivated JEV vaccine, which did not induce CTLs, provided protection to vaccinees against JEV (15). Thus, with a view to develop a recombinant virus-based JEV vaccine, we have constructed RAds synthesizing JEV E protein.

During replication of JEV, the E protein is expressed on the cell surface. Plasmid DNA vectors have been described that synthesize different forms of the E protein, such as the cytoplasmic, membrane-anchored or secretory (2, 6, 7, 15, 20). These different forms of JEV E protein were shown to induce different kind of immune responses. Similarly, recombinants of vaccinia expressing the secretory E protein of Japanese encephalitis or Dengue viruses were found to be highly immunogenic in mice (14, 27, 37). Previously, we had shown that truncated JEV E protein, where the membrane-anchor sequence had been removed by deletion of the C-terminal 102 amino acids, was actively secreted in the cell surroundings (15). We have now constructed RAds that synthesize the membrane-anchored or the secretory E protein.

Oral delivery of RAd has been shown to induce humoral and cellular immune responses to the protein encoded by the transgene, however, these responses have usually been weaker compared to those induced by the IM or intra-peritoneal delivery of RAd (21, 35, 42). In the present study too, oral immunization of mice by RAds resulted in significantly lower anti-JEV antibody titers when compared with the IM route of RAd delivery. Thus, mice immunized IM with 1x10⁸ PFU of RAdEs gave

~60-fold higher anti-JEV antibody response than those immunized with the same dose of the virus given orally.

Use of Sodium carbonate buffer to neutralize the pH of the stomach made no perceptible difference to antibody titers when compared with the antibody titers induced by RAdEs given orally without the bicarbonate buffer. In fact, when bicarbonate buffer was used during oral immunization, the booster doses of RAdEs failed to enhance the anti-JEV antibody titers. For RAdEa too, oral delivery resulted in weaker anti-JEV antibody responses compared to the IM delivery of the recombinant. Thus, compared to oral delivery, IM inoculation of 7.5×10^5 PFU of RAdEa (which was half the dose given orally) induced ~100-fold higher anti-JEV antibody titers. The antibody titers were dose dependent. Thus higher doses of RAdEs (1×10^8 PFU) delivered orally induced higher anti-JEV antibody titers. These titers were ~4-fold higher than those induced by the commercial vaccine given IM. Importantly, IM inoculation of RAdEa or RAdEs at both the doses tested (7.5×10^5 and 1×10^8 PFU) resulted in significantly higher antibody responses than those given by the vaccine; 1×10^8 PFU of RAdEs given IM induced ~250-fold higher titer than the vaccine. Similar pattern was reflected in JEV neutralizing antibody titers when oral route of RAdEs delivery was compared with the IM route although the differences weren't so pronounced. Thus ~20-fold higher JEV neutralizing antibody titers were induced by IM inoculation of 1×10^8 PFU of RAdEs compared to oral delivery of the recombinant. Only statistically insignificant differences were noted in anti-JEV antibody titers induced by 7.5×10^5 PFU of RAdEa and RAdEs given IM. However, there was significant difference in the JEV neutralizing antibody titers generated by the two RAdEs; a mean JEV neutralizing antibody titer of 10 was obtained when mice were immunized with RAdEa whereas it was 133 when mice were immunized with RAdEs. Higher JEV neutralizing antibody titers were recorded when higher doses of RAdEs were used for immunization. At both the doses tested (7.5×10^5 and 1×10^8 PFU) IM inoculation of RAdEs induced significantly higher JEV neutralizing antibody titers than the commercial vaccine. Thus a dose of 1×10^8 PFU of RAdEs given IM induced 8-fold higher JEV neutralization titer than the vaccine. These differences in JEV neutralizing antibody titers induced by RAdEa and RAdEs by oral and IM inoculation were reflected in the level of protection afforded by these recombinants to the immunized mice against lethal JEV challenge. Thus both doses of RAdEs inducing JEV

neutralizing antibody titers higher than the vaccine gave 100% protection. Immunization with RAdEs or RAdEa given orally gave only low levels of protection. Challenge experiments indicated that mice immunized IM with the adenovirus synthesizing the membrane-anchored form of JEV E protein did not develop protective immunity whereas those immunized with recombinant synthesizing the secretory form of JEV E protein developed robust anti-JEV protective immunity resulting in 100% protection. These results show that RAd-based JEV immunizations are superior to naked DNA immunizations, which imparted only about 50-60% protection in a mouse challenge model (15). It is interesting that level of protection was similar (50-60%) when mice were immunized with plasmid DNA synthesizing Ea or Es proteins (15) whereas in the present work Es induced significantly superior protective immune response than the Ea protein. This may be related to a more efficient delivery of JEV transgene using RAd than the direct injection of naked plasmid DNA for immunization. Our finding is, however, consistent with reports from others where truncated form of JEV or Dengue E protein (leading to its secretion) was found to be more immunogenic than the membrane-anchored form of the E protein (14, 37).

Poor anti-JEV antibody induction by oral immunization with RAdEs was also reflected in poor cytokine secretion by splenocytes in presence of JEV. While very little IFN- γ was secreted by splenocytes from mice immunized orally with RAdEs or RAdEa, significant amounts of IFN- γ were secreted by splenocytes obtained from mice immunized IM with RAdEa or RAdEs. Splenocytes from IM immunized mice also synthesized moderate amounts of IL-5 that was not detectable in cultures of splenocytes obtained from mice immunized orally with RAdEs. Mice immunized IM with both RAdEa and RAdEs had significant CTL activity, which was undetectable in mice immunized orally with RAdEs or IM with the vaccine. Oral immunization with RAdEs at lower dose resulted in IgG1 dominated immune responses; ratio of IgG1/IgG2a end-point titers was 6.5. This is consistent with studies on oral immunization of mice with RAd synthesizing rabies glycoprotein where abundance of anti rabies IgG1 was recorded (46). The IM inoculation of RAdEa and RAdEs also resulted in preponderance of IgG1 kind of antibodies. No data could be found in literature on antibody isotypes when adenovirus recombinants are delivered IM. Our results indicating the preponderance of IgG1 type antibodies, secretion of IFN- γ and IL-5 by splenocytes and induction of CTLs suggest that IM inoculation of mice with RAdEs

synthesizing JEV E protein activates both the humoral and the cellular arms of the immune system, and immune responses of both Th1 and Th2 type are induced.

The results presented in this invention show that RAd synthesizing the secretory form of JEV E protein imparted robust immunity in mice against lethal dose of JEV given
5 intra-cerebral. This makes RAdEs a potential candidate vaccine against JEV. Further, safety profile of the vaccine of the instant application was studied. The vaccine is found to be safe for administration. None of the immunized mice showed any obvious complications.

Application Project

<120> Title : A recombinant vaccine against Japanese encephalitis virus (JEV) infection and a method thereof

<130> AppFileReference : IP 1340

<140> CurrentAppNumber : 1516/Del/203

<141> CurrentFilingDate : 2003-12-04

Sequence

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

```

cgtaactata acggctcctaa ggtagcgaaa gctcagatct ggatctcccg atcccctatg   60
gtcgactctc agtacaatct gctctgatgc cgcagatgta agccagatc tgctccctgc   120
ttgtgtgttg gaggtcgtcg agtagtgccg gagcaaat taagctacaa caaggcaagg   180
cttgaccgac aattgcatga agaactcgtc tagggtagg cgttttcgc tgcttcgca   240
tgtacgggcc agatatacgc gttgacattg attattgact agttattaat agtaataat   300
tacggggcca ttagttcata gccatataat gtagttccgc gttacataac ttacggtaaa   360
tggcccgctt ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa tgacgtatgt   420
tcccatagta acgcaaatag ggactttcca ttgacgtcaa tgggtggact atttacggta   480
aactgccac ttggcagtac atcaagtga tcatatgcca agtacgccc ctattgacgt   540
caatgacggt aatggcccg cctggcatta tgccagtac atgaacttat gggactttc   600
tactggcag tacatctaag tattagtcac cgtattacc atggtgatgc ggttttggca   660
gtacatcaat gggcgtgat agcgtttga ctacgggga tttaacgtc tcaacccat   720
tgactcaat gggagttgt ttggcaca aatcaacgg gactttcaa aatgtcgtaa   780
caactcgc acattgacg aatggcgg taggcgtga cgttggagg tcatataag   840
cagagcttc ttgctaacta gagaacac tgcttctgg ctatcgaaa ttaacgac   900
tcactatagg gagaacacg ctgctagcg tttaacggg cctctagac tcagcgggc   960
gocactgtgc ttgatgacg gagctcgta ccattggct cgaacgttg gcagtgtca   1020
tagcttgcgc agggagcatg aagtgtcga attccaggg gaagctttg atgacatca   1080
acaacacgga catcgacgc gttatcgtga ttccacctc aaaaggagag aacagatgt   1140
gggtccgggc aatcgacgtc ggttacatgt gtgaggacac catcagtac gaatgtccta   1200
agcttactgc gggcaatgat ccagaggacg tggattgctg gtgtgacaac caagaagtct   1260
acgtccaata tggacgggtc acgcgacca ggcattccaa gcgaagcagg agatccgtgt   1320
cgggtccagc acatggggag agttcactag tgaataaaaa agaggcttgg ctggattcaa   1380
cgaaagccac acgatatctc acgaaaactg agaactggat cataaggaat cctggctatg   1440
ctttcttggc ggcggtaact ggctggatgc ttggcagtaa caacggtcaa cgcgtggtat   1500
ttaccatcct cctgctgttg gtcgtccgg cttacagttt taattgtctg ggaatgggca   1560
atcgcgactt catagaagga gccagtgag ccactgggtt ggaactgggt ctagaaggag   1620
atagctgttt gacaatcatg gcaaacgata aaccaacatt ggaatgccc atgattaaca   1680
tcgaagctag ccaactgtc gaggtcagaa gttattgcta tcatgctca gtcactgaca   1740
tctcgacggt ggctcgggtc cccatgactg gagaagctca caacgagaag cgagctgata   1800
gtagctatgt gtgcaacaa ggcttactg atcgtgggtg gggcaacgga tgtggacttt   1860
tcgggaaggg aagcattgac acatgtgcaa aattctctg caccagcaa gcgattggga   1920
gaacaatcca gccagaaaac atcaaatag aagttggcat ttttggcat ggaaccacca   1980
cttcggaaaa ccatgggaat tactcagcgc aagttggggc gtcccaggcg gcaagttta   2040
ccgtaacacc caatgctcct tcgataacc tcaacttgg tgactacgga gaagtacac   2100
tggactgtga gccaaaggag ggactgaaca ctgaagcgtt ttacgtcatg accgtgggt   2160
caaagtcat tctgttcat agggaaagt ttcatgacct cgtctcccc tggacgtccc   2220
cttcagcac agcgtggaga aacagagaac tctcatgga attgaagag gcgcacgcca   2280

```

caaaacagtc cgttgttgct cttggttcac aggaaggagg cctccatcag gcgttggcag 2340
 gagccatcgt ggtggagtag tcaagctcag tgaagttaac atcaggccac ctgaaatgta 2400
 ggctgaaaat ggacaaacta gctctgaaag gcacaaacta tggcatgtgt acagaaaaat 2460
 tctcgttcgc gaaaaatccg gcggacactg gtcacggaac agttgtcatt gaactctct 2520
 actctgggag tgatggcccc tgcaaaattc cgattgtctc cgtcgcgagc ctcaatgaca 2580
 tgactcctgt tgggaggctg gtgacagtga accccttgt cgggcttc agtgccaact 2640
 caaagggtct ggtcgagatg gaacccccct tcggagactc ctatatcgtg gttggaagg 2700
 gagacaagca gatcaaccac cattggcaca aataataaag gatctgtgtt ttccccctc 2760
 cccgtgcctt ccttgacctt ggaagggtcc actccactg tcccttcta ataaaatgag 2820
 gaaattgcat cgcattgtct gagtaggtgt cattctattc tgggggtgg ggtggggcag 2880
 gacagcaagg gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggtct 2940
 atggctctg aggcggaag aaccagcaga tctcagatc tgaattcatc tatgtcgggt 3000
 gcggagaaag aggtaatgaa atggcatcga ctgaagatc tgggcgtggt taagggtgg 3060
 aaagaatata taagggtggg gtcttatgta gttttgtatc tgtttgtag cagccgccg 3120
 cgcatgagc accaactcgt ttgatggaag cattgtgagc tcatatttga caacgcgcat 3180
 gcccccatgg gccgggggtg gtcagaatgt gatgggtctc agcattgatg gtcgccccgt 3240
 cctgccgca aactctacta ccttgacctc cgagaccgtg tctggaacgc cgttggagac 3300
 tgcagctcc gccgccgtt cagccgctgc agccaccgoc cgcgggattg tgactgactt 3360
 tgcttccgt agcccgctt caagcagtc agcttccgt tcatccgcc gcgatgaca 3420
 gttagcggct cttttggc aattggattc ttgaccgg gaacttaag tcttttca 3480
 gcagctctg gatctgcgc agcagggttc tgocctgaag gcttctcc ctoocaatgc 3540
 ggtttaaac ataaataaaa aacagactc tgttggatt tggatcaagc aagtgtctg 3600
 ctgtcttat ttagggttt tgcgcgcgc gtaggocgc gaccagcgt ctccgtctt 3660
 gaggctctg tctattttt ocaggactg gtaaggtga ctggatgt tcaatacat 3720
 ggcataagc cgtctctgg ggtggagta gcaactgc agacttcat gtcgggggt 3780
 ggtgtgtag atgacagt cgtagcagg ggcggggc tggctctaa aatgtctt 3840
 cagtaeaa cgtattgca gggcaggoc ctgtgtta gtgttaca agcgttaag 3900
 ctggatgg tgcatcgt gggatagag atgactctg gactgtatt ttagggtgc 3960
 tatgttoca gccatatcc tccgggatt catgtgtgc agaaccaca gcacagtga 4020
 tccgtgcac ttggaaatt tctcatgtag cttagaagg aatgcgtgga agaacttga 4080
 gacgccctg tgacctcaa gattttcat gcattgtcc ataagtag caatggggc 4140
 acggggcgc gctgggca agatatttct gggatcata acgtcatagt tgtgtccag 4200
 gatgagatc tcataggcca tttttacaa gcgcgggcgg aggggtccag actgcggtat 4260
 aatggttca tccggccag gggcgtagt accctcacag atttgcatt cccagcttt 4320
 gagtcagat ggggggatca tgtctacctg cggggcgtg aagaaaacgg ttccgggg 4380
 aggggagatc agctgggaag aaagcagggt cctgagcagc tgcgacttac cgcagccgt 4440
 gggccgtaa atcacacta ttaccggtg caactgttag ttaagagagc tgcagctgcc 4500
 gtcactctg agcagggggg ccacttctt aagcatgtcc ctgactcgca tgttttcc 4560
 gaccaaatcc gccagaaggc gctcgcgcc cagcagatagc agttcttga aggaagcaa 4620
 gtttttcaac ggtttgagac cgtccgctt aggcagctt ttgagcttt gaccaagcag 4680
 ttccaggcgg tccacagct cggcacctg ctctacgga tctgatcca gcatactcc 4740
 tctttcgcg ggttggggcg gctttcgtg tacggcagta gtcggtgct gtccagacgg 4800
 gccagggtca tgtctttca cgggcgcagg gtctctgta gcgtagtct ggtcacggtg 4860
 aagggtgcg ctccgggtcg cgcgtggcc aggggtgct ttaggctggt cctgctggtg 4920
 ctgaagcgt gccgtcttc gccctgcgc tggccagggt agcatttgac catggtgtca 4980
 tagtcagcc cctcgcggc gtggccctg gcgcgcagct tggccttga ggaggcggc 5040
 cagggggc agtgagact tttagggcg tagagcttg gcgcgagaa taccgattcc 5100
 ggggagtagg catccgcgc gcaggcccg cagacggtct gcattccac gagccagggt 5160
 agctcggcc gttcgggtc aaaaaccagg ttcccccat gctttttag gcgtttctta 5220
 cctcgtgtt ccatgagcgc gtgtccagc tcggtgacga aaaggctgtc cgtgtcccc 5280

tatacagact tgagaggcct gtcctcgagc ggtgttccgc ggtcctcctc gtatagaaac 5340
 tcggaccact ctgagacaaa ggctcgcgtc caggccagca cgaaggaggc taagtgggag 5400
 gggtagcggc cgttgtccac taggggggtcc actcgctcca ggggtgtaag acacatgtcg 5460
 cctcttcgg catcaaggaa ggtgattggt ttgtaggtgt aggccacgtg accgggtgtt 5520
 cctgaagggg ggctataaaa ggggggtgggg gcgcgttcgt cctcactctc ttccgcatcg 5580
 ctgtctcga gggccagctg ttgggggtgag tactcctct gaaaagcggg catgacttct 5640
 gcgctaagat tgtcagtttc caaaaacgag gaggatttga tttcacctg gcccgcggtg 5700
 atgcctttga ggggtggcgc atccatctgg tcagaaaaga caatctttt gtgtcaagc 5760
 ttgggtggca acgaccgta gaggcggtg gacagcaact tggcgatgga gcgcagggtt 5820
 tggttttgt cgcgatcggc gcgctcctg gcccgatgt ttagctgcac gtattcgcgc 5880
 gcaacgcacc gccattcggg aaagacgggtg gtgcgctcgt cgggcaccag gtgcacgcgc 5940
 caaccgcggt tgtgcagggt gacaagggtca acgctgggtg ctacctctcc gcgtaggcgc 6000
 tcgttggtcc agcagaggcg gccgcccttg cgcgagcaga atggcggtag ggggtctagc 6060
 tgcgtctcgt ccgggggggtc tgcgtccacg gtaaaagccc cgggcagcag gcgcgcgtcg 6120
 aagtagtcta tcttgcaccc ttgcaagtct agcgcctgct gccatgcgcg ggcggcaagc 6180
 gcgcgctcgt atgggttgag tgggggaccc catggcatgg ggtgggtgag cgcggaggcg 6240
 tacatgccgc aatgtcgt aacgtagagg ggtctctga gtattcaag atatgtaggg 6300
 tagcatctc caccgcggat gctggcgcg acgtaatcgt atagttcgtg caggggagcg 6360
 aggggtcgg gaccgagggt gctacggcg ggtgctctg ctcggaagac tatctgcctg 6420
 aagatggcat gtgagttgga tgatatggtt ggacgctgga agacgttgaa gctggcgtc 6480
 gtgagacctt ccgctcacg cagcaaggag gcgtaggagt cgcgagcgtt gttgaccagc 6540
 tcggcggtga cctgcacgtc tagggcgag tagtccaggg ttctctgat gatgcatac 6600
 ttatctgtc cctttttt ccacagctc cggttgagga caactcttc gcggtcttc 6660
 cagtactctt ggatcggaaa ccgtcggcc tccgaacggt aagagctag catgtagaac 6720
 tggtagcgg cctggtaggc gcagcatccc ttctacgg gtagcgcta tgcctgcgc 6780
 gcctccgga gcgaggtgtg ggtgagcgca aagggtctcc tgaccatgac ttgaggtagc 6840
 tggatttga agtcagtgct gtgcaccc cctgctccc agagcaaaaa gtccgtgcgc 6900
 tttttgaa gcggttttgg caggcggaag gtgacatcgt tgaagagtat ctttccgcg 6960
 cgaggcataa agttgcgtgt gatcggaag ggtcccgca cctcggaacg gttgttaatt 7020
 acctggcgcg cgagcagat ctgctcaag ccgttgatgt tgtggccac aatgtaaagt 7080
 tccaagaagc gcgggatgcc ctgatggaa ggcaatttt taagtcttc gtaggtgagc 7140
 tcttcagggg agctgagccc gtgctctga agggccagt ctgcaagatg agggttggaa 7200
 gcgacgaatg agctccacag gtcacgggcc attagcattt gcagggtggtc gcgaaaggct 7260
 ctaactggc gacctatggc cttttttct ggggtgatgc agtagaagg aagcgggtct 7320
 tgttccagc ggtcccatcc aagggtcgc gctaggctc gcgcggcagt cactagaggc 7380
 tcatctcgc gaacttcat gaccagcatg aagggcacga gctgctccc aaaggcccc 7440
 atccaagtat aggtctctac atcgtagggtg acaaagagac gtcgggtgcg aggatgcgag 7500
 ccgatcggga agaactggat ctcccgcac caattggagg agtggctatt gatgtggta 7560
 aagtagaagt cctgcgcag ggcggaacac tctgctggc ttttgtaaa acgtgcgag 7620
 tactggcagc ggtgcacggg ctgtacatcc tgcagaggt tgacctgac accgcgcaca 7680
 aggaagcaga gtgggaattt gagccccctg cctggcgggt ttggctggtg gtcttctact 7740
 tcggctgctt gtcttgacc gtctggctg tcgaggggag ttacgggtga tcggaccacc 7800
 acgccgcgc agcccaagt ccagatgtcc gcgcgcggcg gtcggagctt gatgacaaca 7860
 tcgcgcagat gggagctgtc catggtctgg agtcccccg gcgtcaggctc aggcgggagc 7920
 tcctgcaggt ttacctcga tagacgggtc agggcgcggg ctagatccag gtgataccta 7980
 atttcagggt gctgggtggt ggcgcgctc atggcttga agaggccga tccccgcgc 8040
 gcgactacgg taccgcgcgg cggcgcggtg gcccggggg tgccttga tgatcatct 8100
 aaaagcgggt acgcggcgga gccccggag gtaggggggg ctccggacc gccgggagag 8160
 ggggcagggg cagctcgcg ccgcgcggg gcaggagctg gtgctgcgc cgtaggtgct 8220
 tggcgaacgc gacgacgcgg cggttgatct cctgaatctg gcgcctctgc gtgaagacga 8280

cgggccccgt gagcttgaac ctgaaagaga gttcgacaga atcaatttcg gtgtcgttga 8340
 cggcgccctg gcgcaaaatc tctcgacgt ctctgagtt gtcttgatag gcatctcgg 8400
 ccatgaactg ctcgatctct tctctctgga gatctccgcg tccggctcgc tccacgggtg 8460
 cggcgaggtc gttggaaatg cgggccatga gctcgagaa ggcgttgagg cctccctcgt 8520
 tccagacgcg gctgtagacc acgccccctt cggcatcgcg ggcgcgcg accacctcgc 8580
 cgagattgag ctccacgtgc cggcggaaga cggcgtagtt tcgaggcgcg tgaagagggt 8640
 agttgagggt ggtggcgggtg tgttctgcca cgaagaagta cataaccag cgtcgcaacg 8700
 tggattcgtt gatatcccc aaggcctcaa ggcgctccat ggctcgtag aagtcacgg 8760
 cgaagttaa aaactgggag ttgcgcgcg acacgggtta ctctctcc agaagacgga 8820
 tgagctcggc gacagtgtcg cgcacctgc gctcaaaggc tacaggggccc tcttctctt 8880
 cttaatctc ctctccata agggcctccc ctctcttc tctggcggc ggtgggggag 8940
 gggggacacg gcggcgacga cggcgaccg ggaggcggc gacaaagcg tcatcatct 9000
 ccccgccgcg acggcgcatg gtctcggta cggcgccggtt gtctcgcgg gggcgagtt 9060
 ggaagacgcc gcccgcatg tcccggttat ggttgccgg gggcgctgcca tgcggcagg 9120
 atacggcgt aacgatgcat ctcaacaatt gttgttagg tactccgcg ccgagggacc 9180
 tgagcgagtc cgcacgacc ggcacgaaa acctctcgag aaaggcgtct aaccagcac 9240
 agtcgcaagg taggctgagc accgtggcgg gcggcagcgg gcggcggtcg ggttggttc 9300
 tggcgagggt gctgctgag atgtaattaa agtaggcggt cttgagacgg cggatggtcg 9360
 acagaagcac catgtcctt ggtccggct gctgaatgcg caggcggtcg gccatgcccc 9420
 aggttcgtt ttgacatcgg cgcaggctct ttagtagtc ttgcatgagc ctcttaccg 9480
 gcactcttc ttctcttcc tctgtctg catctctgc atctatcgt gcggcgccg 9540
 cggagtttgg cgtaggtgg gccctctc ctccatgcg tctgacccg aagccctca 9600
 tccgtgaag caggcgtagg tccgagcaa cgcgctcggc taatagcc tctgacact 9660
 gcgtgagggt agctgggaag tcatcatgt ccacaaagcg gtggtatcg cctgtgtga 9720
 tgggtgaagt gcagttggc ataaccgac agttaacgt cgggtgccc ggcgcgaga 9780
 gctcgggtga cctgagacgc gactaagcc tgcagtaaa tccgtatcg ttcaagtc 9840
 gcaccaggta ctggtatcc accaaaaagt gcggcgccg cggcggtag agggccagc 9900
 gtaggtggc cggggctccg gggcgagat ctccaacat aaggcgatga tatccgtaga 9960
 gtacctgga catccagggt atgcggcgcg cgggtgtgga ggcgcgcgga aagtcgcgga 10020
 cgcggttcca gatgtgcgc agcgcaaaa agtgcctcat ggtcgggacg ctctggcgg 10080
 tcaggcgcg ccaatgttg acgcttagc gtgcaaaagg agagcctgta agcgggact 10140
 ctccgtgtg ctggttgata aattcgcaag ggtatcatgg cggacgacg ggttcgagc 10200
 cccgtatcg gccgtccgc gtgatcatg cggttaccgc ccgctgtcg aaccagggtg 10260
 tgcgacgtca gacaacgggg gagtgtctt tttggcttc ttccaggcgc ggcggctgt 10320
 gcgctagct ttttgccac tggcgcgcg cagcgtaac ggttaggctg gaaagcgaaa 10380
 gcattaagt gctcgtccc ttagccgga ggttatctt ccaagggtt agtcgcggga 10440
 cccccgttc ggtctcga cggccggac tgcggcgaac gggggtttgc ctccccgtca 10500
 tgcaagacc cgttgcaaa ttctccgga aacagggacg agccccctt ttgcttttc 10560
 cagatgcat cgggtgtcg gcagatcgc cccctctc agcagcgga agagcaagag 10620
 cagcggaaga catgagggc accctccct ctctaccg cgtcaggagg ggcgacatcc 10680
 gcggttgac cgcgacga tgggtattac gaacccccg gcgcggggc ccggcactac 10740
 ctggacttg agggaggcga gggcctggcg cggctaggag gccctctc tagcggcac 10800
 ccaagggtg agctgaagc gtatagcgt gaggcgtac tgcggcgca gaacctgtt 10860
 cgcgaccgc agggagagga gccgaggag atcgggatc gaaagttcca cgcaggcg 10920
 gagctgcgc atggcctgaa tgcgagcgg ttgctcgcg agggaggact tagcccgac 10980
 gcgcgaacc ggattagtc cgcgcgcga cagtgccgg ccgccacct ggtaacgca 11040
 tacgagcaga cggtaacca ggagattaac ttcaaaaaa gcttaacaa ccagtcgt 11100
 acgctgttg cgcgcgagga ggtggctata gactgatgc atctgtggga cttgtgaagc 11160
 gcgctggagc aaaacccaa tagcaagcg ctcagggcg agctgttct tatagtgcag 11220
 cacgagggg acaacgaggc attcaggat gcgctgtaa acatagtaga gcccaggggc 11280

cgctggctgc tcatattgat aaacatcctg cagagcatag tgggtcagga ggcagcttg 11340
 agcctggctg acaaggtggc cgccatcaac tatccatgc ttagcctggg caagttttac 11400
 gcccgaaga tataccatac cccttacgtt cccatagaca aggaaggtaaa gatcgagggg 11460
 ttctacatgc gcatggcgtc gaaggtgctt acctgagcg acgacctggg cgtttatcgc 11520
 aacgagcgca tccacaaggc cgtgagcgtg agccggcggc gcgagctcag cgaccgcgag 11580
 ctgatgcaca gcctgcaaag ggccctggct ggcaaggga gcggcgatag agaggccgag 11640
 tcctactttg acgcgggcgc tgacctgcgc tggggcccaa gccgacgcgc cctggaggca 11700
 gctggggcgc gacctgggct ggcggtggca cccgcgcgc ctggcaactg cggcgggctg 11760
 gaggaatatg acgaggacga tgagtacgag ccaggaggcg gcgagtacta agcggctgat 11820
 tttctgatca gatgatgcaa gacgcaacgg acccgcggtt gcggcgggcg ctgcagagcc 11880
 agccgtccgg ccttaactcc acggagcact ggcccgaggt catggaccgc atcatgtcgc 11940
 tgactgcgc caatcctgac gcgttcggc agcagccgca ggccaaccgg ctctccgcaa 12000
 ttctggaagc ggtgggtccc gcgcgcgcaa accccacgca cgagaagggt ctggcgatcg 12060
 taaacgcgtc ggccgaaaac agggccatcc ggcccgacga ggccggcctg gtctacgacg 12120
 cgctgctca gcgcgtggct cgttaaca gcggcaactg gcagaccaac ctggaccggc 12180
 tgggggggga tgtgcgcgag gccgtggcg agcgtgagcg gcgcgagcag cagggcaacc 12240
 tgggctccat gggtgcacta aacgccttc tgagtacaca gcccgccaac gtgcccggg 12300
 gacaggagga ctacaccaac ttgtgagcg cactgcggtt aatgggtgact gagacaccg 12360
 aaagtggagt gtaccagtct ggccagact atttttoca gaccagtaga caaggcctgc 12420
 agaccgtaa cctgagccag gctttcaaaa actgcaggc gctgtggggg gtgcgggctc 12480
 ccacaggcga ccgcgcgacc gtgtctagct tgcagcgc caactcgc ctgtgtcgc 12540
 tgctaatagc gcccttcacg gacagtggca gcgtgtccg ggacacatac ctaggctact 12600
 tgctgacct gtaccgcgag gccataggct aggcgcagt ggacgagcat actttccagg 12660
 agattacaag tgcagccgc gcctggggc agggagcac ggccagctg gaggcaacc 12720
 taaactaact gctgaacaac ccggcgaga agatccctc gttgcagct taaacagc 12780
 agggaggcgc cattttgcg tactgtacg agagcgtgag ccttaacctg atgcgcgac 12840
 gggtaacgc cagcgtggcg ctggacatga ccgcgcgcaa catggaaacc ggcagtgtg 12900
 cctcaaacgc gccgtttatc aaccgcctaa tggactact gcatcgcgc gccgcgtga 12960
 acccgagta tttaaccaat gccatctga accgcactg gctacccgc cctggttct 13020
 acaccggggg attcgagggt ccggagggt acgatggatt cctctgggac gacatagacg 13080
 acagcgtgtt tccccgcaa ccgcagacc tgctagagt gcaacagcgc gacagggcag 13140
 aggcggcgtc gcgaaaggaa agcttcgcga ggccaagcag ctgtccgat ctaggcgtg 13200
 cggccccgcg gtcagatgct agtagccat ttcaagctt gatagggtct ctaccagca 13260
 ctgcaccac ccgcccgcgc ctgctggcg agggaggagta cctaacaac tcgctgctgc 13320
 agccgcagcg cgaaaaaac ctgcctcgg catttccaa caacgggata gagagcctag 13380
 tggacaagat gtagtagtgg aagacgtac gcaggagga cagggacgtg ccaggcccgc 13440
 gcccggccac ccgtcgtcaa aggcacgacc gtcagcggg tctgggtgg gaggacgatg 13500
 actcggcaga cgacgcagc gtcctggatt tgggaggag tggcaaccgc ttgcgcacc 13560
 ttgcgccag gctggggaga atgttttaa aaaaaaaaaa gcatgatgca aaataaaaaa 13620
 ctaccaaagg ccatggcacc gagcgttgg ttcttgtat tccccctagt atgcgcgcgc 13680
 cggcgatgta tgaggaaagt cctcctccct cctacgagag tgggtgagc gcggcgccag 13740
 tggcgcggc gctgggttct ccctcgatg ctcccctgga cccgcggtt gtgctccgc 13800
 ggtacctgc gcctaccggg gggagaaaca gcatccgta ctctgagtg gacccctat 13860
 tcgacaccac ccgtgtgtac ctggtggaca acaagtcaac ggatgtggca tcctgaact 13920
 accgaacga ccacagcaac ttctgacca cggctattca aaacaatgac tacagcccg 13980
 gggaggcaag cacacagacc atcaatctg acgaccggtc gactggggc ggcgacctga 14040
 aaaccatct gcataccaac atgcaaatg tgaacgagt catgtttacc aataagtta 14100
 aggcgcgggt gatggtgtc gcctgccta ctaaggacaa tcaggtggag ctgaataacg 14160
 agtgggtgga gttcacgctg ccgagggca actactcga gaccatgacc atagacctta 14220
 tgaacaacgc gatcgtggag cactactga aagtgggag acagaacggg gttctggaaa 14280

gcgacatcgg ggtaaagttt gacacccgca acttcagact ggggtttgac cccgtcactg 14340
gtctgtcat gcctggggta tatacaaacg aagccttcca tccagacatc attttgctgc 14400
caggatgcgg ggtggacttc acccaagcc gcctgagcaa ctgttgggc atccgcaagc 14460
ggcaaccctt ccaggaggcg ttaggatca cctacgatga tctggagggt ggtaacattc 14520
ccgactgtt ggatgtggac gctaccagg cgagcttga agatgacacc gaacaggcg 14580
gggtggcg aggcggcagc aacagcagt gcagcggcg ggaagagaac tccaacgagg 14640
cagccgaggc aatgcagccg gtggaggaca tgaacgatca tgccattcgc ggacacact 14700
ttgccacagc ggtgaggagc aagcgcgctg aggcggaagc agcggccgaa gctccgccc 14760
ccgctgcgca acccgaggtc gagaagcctc agaagaaacc ggtgatcaaa cccctgacag 14820
aggacagcaa gaaacgcagt tacaacctaa taagcaatga cagcaccttc acccagatcc 14880
gcagctggta ccttgcatc aactacggcg accctcagac cggaatccgc tcatggaccc 14940
tgctttgac tctgacgta accctggct cgaggcagg ctactggtcg ttgcagaca 15000
tgatgcaaga cccgtgacc ttccgctcca cgcgccagat cagcaacttt ccggtgggtg 15060
gcccggagct gttgcccgtg cactccaaga gtttctaca cgaccaggcc gtctactccc 15120
aactatccg ccagtttacc tcttgaccc acgtgttcaa tgcctttccc gagaaccaga 15180
ttttggcgcg cccgccagcc ccaccatca ccaccgtcag tgaacacgtt cctgctctca 15240
cagatcacgg gacgctaccg ctgcgaaca gcatcggagg agtccagcga gtgaccatta 15300
ctgacgccag acgcccagc tgcctctacg ttacaaggc cctgggcata gtctgcgcg 15360
ggtctctatc gagccgact ttttagcaa gcatgtccat ccttatatcg ccagcaata 15420
acacaggctg gggcctgcgc ttccaagca agatgtttgg cggggccaag aagcgtccg 15480
accaacaccc agtgcgcgtg cgcgggcact accgcgcgc cgggggcgcg cacaacgcg 15540
gocgactgg gcgcaccac gtcgatgacg ccacgacgc ggtgggtggg gaggcgcgca 15600
actacagcc cagccgcca ccagtgtca cagtggacgc ggccattcag accgtggtgc 15660
gcccagccg gcgctatgct aaatgaaga gacggcgagg gcgctagca cgtcgcaac 15720
gocgocgac cggcactgoc gccaacgcg cggcggggc cctgctaac cgcgcagtc 15780
gcaocggcg accggcgcc atgcggcgcc ctggaaggc ggcggcggt attgtcactg 15840
tgccccagc gtcaggcga cagcggcgcc ccgagcagc cgcggccatt agtgcctaga 15900
ctcagggtcg caggggcaac gtgtattggg tgcgcgact ggtagcggc ctgcgcgtg 15960
ccgtgcgac cgcggccgc cgaactaga ttgaagaa aaactacta gactcgtact 16020
gttgtatgta tccagcggc gcggcgcgca acgaagctat gtccaagcgc aaatcaag 16080
aagagatgct ccaggtcatc gcggcgaga tctatggccc ccgaagaag gaagagcagg 16140
attacaagcc ccgaagcta aagcgggtca aaaaagaaaa gaaagatgat gatgatgaac 16200
ttgacgca ggtggaactg ctgcagccta ccgcggccag gcgacgggta cagtggaaa 16260
gtcgaagcgt aaacgtgtt ttgcgacccg gcaccaccgt agtctttacg cccggtgagc 16320
gctccaccg cactacaag cgcgtgtatg atgagggtga cggcgacgag gacctgctg 16380
agcaggccaa cgagcgctc ggggagtttg cctacggaaa gcggcataag gacatgctg 16440
cgttgccgt ggacgagggc aaccaacac ctacgctaaa gccgtaaca ctgcagcagg 16500
tgctgcccgc gcttgaccg tccgaagaaa agcggcgcc aaagcgcgag tctggtgact 16560
tggaaccac cgtgcagctg atggtacca agcggcagc actggaagat gtcttgaaa 16620
aaatgaccgt ggaacctggg ctggagccc aggtccgct gcggccaatc aagcaggtg 16680
cgccgggact gggcgtgag accgtggagc ttcagatacc cactaccagt agcaccagta 16740
ttgccaccgc cacagagggc atggagacac aaacgtcccc ggttgctca gcggtggcg 16800
atgccgggt gcaggcggtc gctgcggcg cgtccaagac ctctacggag gtgcaaacg 16860
accgtggat gtttcgctt tcagccccc ggccggcg ccgttcgagg aagtagggc 16920
ccgcagcgc gctactccc gaatatgccc tacatcttc cattgcgct accccggct 16980
atcgtggcta cactaccgc ccgaagac gagcaactac ccgacggcga accaccactg 17040
gaacccggc ccgcgctgc cgtcgccagc ccgtgctggc cccgatttcc gtgcgagg 17100
tggtcgca aggaggcagg accctggtgc tgccaacagc gcgctaacac ccagcatc 17160
tttaaaagc ggtctttgtg gttcttcag atatggccct cactgcgcg ctccgttcc 17220
cgggtccggg attccagga agaatacacc gtagggggg catggccggc cagggctga 17280

cggggcgcat gcgtcgtgcg caccaccggc ggccggcgcg gtcgaccgt cgcgtgcgcg 17340
 gcggtatcct gccctcctt attccactga tcgcccggc gattggcgcc gtgcccggaa 17400
 ttgcatccgt ggcccttcag gcgcagagac actgattaaa aacaagttgc atgtggaaaa 17460
 atcaaaataa aaagtctgga ctctcacgct cgcttggtcc tgaactatt ttgtagaatg 17520
 gaagacatca actttgcgtc tctggccccc cgacacggct cgcgccggtt catgggaaac 17580
 tggcaagata tcggcaccag caatatgagc ggtggcgccct tcagctgggg ctgcctgtgg 17640
 agcggcatta aaaatttcgg ttccaccgtt aagaactatg gcagcaaggc ctggaacagc 17700
 agcacaggcc agatgctgag ggataagttg aaagagcaaa atttccaaca aaaggtggta 17760
 gatggcctgg cctctggcat tagcgggggtg gtggacctgg ccaaccaggc agtgcaaaat 17820
 aagattaaca gtaagcttga tccccgccct cccgtagagg agcctccacc ggccgtggag 17880
 acagtgtctc cagagggggcg tggcgaaaag cgtccgcgcc ccgacaggga agaaactctg 17940
 gtgacgcaaa tagacgagcc tccctcgtac gaggaggcac taaagcaagg cctgccacc 18000
 accgtccca tcgcgccat ggctaccgga gtgctgggccc agcacacacc cgtaacgctg 18060
 gacctgcctc cccccgccga caccagcag aaacctgtgc tgcaggccc gaccgcgtt 18120
 gttgtaacc gtcctagccg cgcgtccctg gcgcgcgcgc ccagcggicc gcgatcgtt 18180
 cggccctag ccagtggcaa ctggcaaagc aactgaaca gcactgtggg tctgggggtg 18240
 caatccctga agcgcgcagc atgcttctga tagctaactg gtcgtatgtg tgcaltgtat 18300
 gcgtccatgt cgcgccaga ggagctgctg agccgcgcgc cgcgccctt ccaagatggc 18360
 tacccttcg atgatccgc agtggctta catgcacatc tcgggccagg acgctcggga 18420
 gtacctgagc cccgggctgg tgcagtttgc ccgcgccacc gagacgtact tcagcctgaa 18480
 taacaagttt agaaccacca cgttggtgccc tacgcagac gtgaccagc accggtcca 18540
 gcgttgacg ctgcggttca tccctgtgga ccgtgaggat actgcgtact cgtacaaggc 18600
 gcggttacc ctactgtgg gtgataaccg tctgtggac atggcttcca cgtacttga 18660
 ctcccgccg gtgctggaca ggggocctac ttttaagoc tactctgga ctgctaca 18720
 cgccctggct cccaagggtg ccccaaatc ttgcgaatgg gatgaagctg ctactgct 18780
 tgaataaac ctagaagaag aggcagatga caacgaagc gaagtagac agcaagctga 18840
 gcagcaaaaa actcacgtat ttgggcaggc gccttattct ggtataata ttacaaggga 18900
 ggggtattca atagggtgc aagggtcaac acctaatat gccgataaaa catttcaac 18960
 tgaacctcaa ataggagaat ctactgtga cgaacagaa attaatcatg cagctgggag 19020
 agtccataaa aagactacc caatgaaacc atgttacggt tcatatgcaa aaccacaaa 19080
 tgaatatgga gggcaaggca ttcttgtaaa gcaacaaaat ggaagctag aaagtcaagt 19140
 ggaatatcaa tttttctaa ctactgaggc agccgcaggc aatggtgata actgactcc 19200
 taaagtgtga ttgtacgtg aagatgtaga tatagaacc ccagacactc atatttctta 19260
 catgccact attaaggag gtaactcac agaactaat ggccaacaat ctatgccaa 19320
 caggccaat tacattgctt ttagggacaa tttatttgt ctatgtatt acaacagcac 19380
 gggtaatatg ggtgttctgg cgggccaagc atcgagttg aatgctgtg tagatttga 19440
 agacagaac acagagctt cataccagct ttgcttgat tccattgtg atagaaccag 19500
 gtactttct atgtggaatc aggtgttga cagctatgat ccagatgta gaattattga 19560
 aatcatgga actgaagatg aacttcaaa ttactgctt cactgggag gtgtgattaa 19620
 tacagagact cttaaccaag taaaacctaa aacagggtcag gaaaatggat gggaaaaaga 19680
 tgcacagaa ttttcagata aaaatgaaat aagagttgga aataatttg ccatggaaat 19740
 caatctaat gccaacctgt ggagaaattt cctgtactcc aacatagcgc tgtatttgc 19800
 cgacaagcta aagtacagtc ctccaacgt aaaaatttct gataaccac acacctaga 19860
 ctacatgaac aagcgagtg tggctcccgg gctagtggac tgcatacta acctggagc 19920
 acgtgtgtcc ctgactata tggacaacgt caaccattt aaccaccacc gcaatgctgg 19980
 cctgcgtac cgtcaatgt tgcgtggcaa tggctgctat gtgcccttc acatccagg 20040
 gcctcagaag ttctttgcca ttaaaaacct ctttctctg ccgggtcat acacctaga 20100
 gtggaaactt aggaaggatg ttaacatggt tctgcagagc tccctaggaa atgacctaa 20160
 ggttgacgga gccagcatta agttgatag catttgcct tacgccact tcttcccat 20220
 ggcccacaac accgctcca cgcttgaggc catgctaga aacgacacca acgaccagt 20280

cttaacgac tatctctccg ccgccaacat gctctaccct ataccgcca acgctacca 20340
 cgtgccata tccatccct ccgcaactg ggcggcttc cgcggctggg ccttcacgcg 20400
 ccttaagact aaggaaacc catcactggg ctggggctac gaccttatt acacctactc 20460
 tggctctata ccttacctag atggaacct ttacctcaac cacacctta agaagggtggc 20520
 cattaccttt gactctctg tcagctggcc tggcaatgac cgctgctta ccccaacga 20580
 gtttgaatt aagcgctcag ttgacgggga gggttacaac gttgccagt gtaacatgac 20640
 caaagactgg ttctgtgtac aaatgctagc taactataac attggctacc agggcttcta 20700
 tatccagag agctacaagg accgcatgta ctcttcttt agaaactcc agcccatgag 20760
 ccgtcagggt gtggatgata ctaatacaa ggactacca cagggtggga tcttaccca 20820
 acacaacaac tctggatttg ttggctacct tgccccacc atgcgcgaag gacaggccta 20880
 cctgctaac ttccctatc cgcttatagg caagaccgca gttgacgca ttaccagaa 20940
 aaagtittct tgcatcgca cctttggcg catccattc tccagtaact ttatgtccat 21000
 gggcgcatc acagacctgg gccaaaacct tctctagcc aatccggcc acgctaga 21060
 catgactttt gagggtggtc catggacga gccacccct tttatgttt tgttgaagt 21120
 cttgacgtg gtccgtgtgc accagccgca ccggcgctc atcgaaaccg tgtacctgcg 21180
 cagcccttc tcggccggga ccgccaacac ataaagaagc aagcaacatc aacaacagct 21240
 gccgccatgg gctccagtga gcaggaaactg aaagccattg tcaaatatct tgggtgtggg 21300
 ccatattttt tgggaccta tgacaagcgc ttccaggct ttgtttctcc acacaagctc 21360
 gcctgcgca tagtcaatac ggcggctgc gagactgggg gcgtacactg gatggccttt 21420
 gcttgaacc cgcactcaaa aacatgctac ctcttgagc cctttggct ttctgaccag 21480
 cgactcaagc aggtttacca gtttgatgac gactcactcc tgcgcgtag cgccattgct 21540
 tcttccccg accgctgtat aacgctggaa aagtccacc aaagcgtaca ggggccaac 21600
 tcggcgctt gtggactatt ctgctcatg ttctccacg cctttgcaa ctggcccaa 21660
 actccatgg atcacaacc caccatgaac ctattacg ggtaccca ctcatgctc 21720
 aacagtccc aggtacagc caoctcgt cgaaccagg aacagctta cagttctg 21780
 gagcgccact cgcctactt ccgagocac agtcgcaga ttaggagcgc cacttttt 21840
 tgtacttga aaaacatga aaataatgt actagagaca cttaataa aggcaaatgc 21900
 tttatttgt acactctcg gtgattattt accccacc ttgcgctcg cgcggttaa 21960
 aaatcaaagg ggttctgcg cgcacgccta tgcgccatg gcagggaac gttcgatc 22020
 tgggttttag tgcctcactt aaactcaggc acaaccatc gcggcagctc ggtgaagtt 22080
 tcactccaca ggtcgcgc catcacaac gcgttagca ggtcggcgcg cgatatctg 22140
 aagtcgagt tggggcctc gccctgcgc cgcgagttg gatcacagg gttgcagc 22200
 tggaaacta tcagcgccg gttgtgcag ctggccagca cgtctgtc ggagatcaga 22260
 tccgctcca ggtctcgc gttgtcagg gcgaacggag tcaacttgg tagctgcct 22320
 cccaaaaagg gcgcgtgccc aggtttgag ttgcactgc accgtagtgg catcaaaagg 22380
 tgaccgtcc cggctggggc gttaggatac agcgcctga taaaagcctt gatctgcta 22440
 aaagccact gagccttgc gccttcagag aagaacatgc cgcaagact gccgaaaac 22500
 tgattggcg gacaggcgc gtcgtgcag cagcacctg cgtcggtgtt ggagatctg 22560
 accacattc ggccccacc gttcttcag atctggct tctagactc ctcttcagc 22620
 gcgctgccc cgttttgc ctgcacatc atttcaatc cgtgctctt atttatcata 22680
 atgcttcgt gtagacactt aagctgcct tcgatctcag cgcagcggg cagccacaac 22740
 gcgcagccc tgggctcgt atgctgtag gtcacctc caaacgactg caggtacgcc 22800
 tgcaggatc gcccatcat cgtcacaag gcttgtgc tgggaaggc cagctgcaac 22860
 ccgggtgct cctgttcag ccaggcttg catagggcc cagagcttc cacttggtca 22920
 ggcatagtt tgaagttgc cttagatcg ttatccact ggtactgtc catcagcgcg 22980
 cgcgcagct ccatgccct cccccagca gacagatc gcacactcag cgggttcatc 23040
 accgtaatt cacttccgc ttgcgtggg tcttctctt ccttgcgt ccgcatacca 23100
 cgcgccatg ggtcgtctt attcagccgc cgcactgtc gcttacctt ttgccatgc 23160
 tggattaga ccgggtgggt gctgaaacc accatttga gcgccatc ttctttct 23220
 tctcgtgt ccagattac ctctggtgat ggcggcgct cgggctggg agaaggcgc 23280

tcttttttct tcttgggctc aatggccaaa tccgccgccg aggtcgatgg ccgctggctg 23340
gggtgtgcgc gcaccagcgc gtctgtgat gagtcttct cgtctcggga ctgcatacgc 23400
cgccctatcc gcttttttgg gggcgcccg ggaggcggcg gcgacgggga cggggagcgc 23460
acgtctcca tggttggggg acgtcgccgc gcaccgcgtc cgcgtcggg ggtggttctg 23520
cgtgctctct ctcccgact ggccatttcc ttctctata ggcagaaaa gatcatggag 23580
tcagtcgaga agaaggacag cctaaccgcc cctctgagt tcgccaccac cgctccacc 23640
gatgcccca acgcgcctac cacttcccc gtcgaggcac ccccgctga ggaggaggaa 23700
gtgattatcg agcaggaccc aggttttcta agcgaagacg acgaggaccg ctcatgacca 23760
acagaggata aaaagcaaga ccaggacaac gcagaggcaa acgagggaaca agtcgggctg 23820
ggggagcaaa ggcattggcg ctacctagat gtgggagacg acgtgctgtt gaagcatctg 23880
cagcgccagt gcgcattat ctgcgacgc ttgcaagagc gcagcgatgt gccctcgc 23940
atagcggatg tcagccttgc ctacgaacgc cactattct caccgcgct acccccaaa 24000
cgccaagaaa acggcacatg cgagccaac ccgcgcctca acttctacc cgtatttgc 24060
gtgccagggg tgcctggcac ctatcacatc ttttccaa actgcaagat accctatcc 24120
tgccgtgcca accgcagccg agcggacaag cagctggcct tgcggcaggg cgtgtcata 24180
cctgatatcg cctcgtcaa cgaagtcca aaaatcttg agggcttgg acgcgacgag 24240
aagcgcgcgg caaacgctct gcaacaggaa aacagcgaat atgaaagtca ctctggagt 24300
ttggtggaac tcgagggtga caacgcgcgc ctgacctac taaaacgcag catcaggctc 24360
accactttg cctaccggc actaaccta cccccaagg tcatgagcac agtcatgagt 24420
gagctgatcg tgcgcctgc gcagccctg gagaggatg caaatttga agaacaaca 24480
gaggaggcc taccgcagt tggcgacgag cagctagcgc gctggcttca aacgcgcgag 24540
cctccgact tggaggagcg acgcaacta atgatggcgc cagtgtcgt taccgtggag 24600
cttgagtga tgcagcggtt ctgtctgac ccggagatgc agcgaagct agaggaaaca 24660
ttgactaca ccttgcga gggctagta cgcaggct gcaagatct caacgtggag 24720
ctctgcaac tggcttcta ccttgaatt ttgcagaaa accgcttgg gcaaacgtg 24780
ctcatcca cgtcaagg cgaggcggc cgcgactacg tgcgactg cgttactta 24840
ttctatgt acactggca gacggcatg ggcgttggc agcagtgtt ggaggagtgc 24900
aacctcaagg agctgcaga actgctaaag caaaactga aggacctatg gacggcttc 24960
aacgagcgt cgtggccgc gcactggcg gacatcatt tcccgaacg cctgcttaa 25020
acctgcaac agggctgccc agacttacc agtcaagca tgttcagaa cttaggaac 25080
ttatctag agcgtcagg aatcttccc gccactgct gtgacttcc tagcattt 25140
gtgcccatta agtaccgga atgcccgc cgccttggg gccactgcta cttctgag 25200
ctagccaact accttgcta cactctgac ataattgaag acgtgagcgg tgacggctta 25260
ctggagtgc actgtcgtg caacctatg accccgacc gctccctgt ttgcaattc 25320
cagctgcta acgaaagtca aattatcgtt accttgagc tgcagggtcc ctgcctgac 25380
gaaaagtccg cggctcggg gttgaaactc actccggggc tgtggacgtc ggcttacctt 25440
cgcaaatgt tacctgagga ctaccagcc cagagatta ggttctacga agaccaatcc 25500
cgccgccta atgcggagct tacgcctgc gtcattacc agggcccat tcttgccaa 25560
ttgcaagcca tcaacaagc ccgcaagag ttctgctac gaaaggagc gggggttac 25620
ttggatcccc agtccggcga ggagctaac ccaatcccc cgccgcgca gccctatcag 25680
cagcagccgc gggcccttgc tcccaggat ggcacccaaa aagaagctgc agctgccgc 25740
gccaccacg gacgaggagg aatctggga cagtacgca gaggaggtt tggacgagga 25800
ggaggaggac atgatggaag actgggagag ctagacgag gaagcttcc aggtcgaaga 25860
ggtgtcagac gaaacaccgt caccctcgt cgattcccc tcgccggcg ccagaaatc 25920
ggcaaccggt tcagcatgg ctacaactc cgtctctag gcgccggcg cactgcccgt 25980
tcgccgccc aaccgtatg gggacaccac tggaaaccag gccggtagt ccaagcagcc 26040
gccgccgta gcccaagag aacaacagc ccaaggctac cgtcatggc gcgggcaca 26100
gaagccata gttgcttct tgcaagactg tgggggcaac atctcttcg cccgccgtt 26160
tcttctac catcagcg tggcctccc cgtaacatc ctgattact accgtatct 26220
ctacagcca tactgcaccg gcggcagcgg cagcaacagc agcgccaca cagaagcaa 26280

ggcgaccgga tagcaagact ctgacaaagc ccaagaaatc cacagcgcg gcagcagcag 26340
 gaggaggagc gctgcgtctg gcgccaacg aaccgtatc gaccgagcag cttagaaaa 26400
 ggatttttcc cactctgtat gctatatttc aacagagcag gggccaagaa caagagctga 26460
 aaataaaaaa caggctctcg cgatccctca cccgagctg cctgtatcac aaaagcgaag 26520
 atcagcttcg gcgcacgctg gaagacgagg aggcctctct cagtaaatac tgcgcgctga 26580
 ctcttaagga ctagtctgc gccctttctc aaatttaagc gcgaaaacta cgtcatctcc 26640
 agcgccaca cccggcgcca gcacctgtg tcagcgccat tatgagcaag gaaattccca 26700
 cgccctacat gtggagtac cagccacaaa tgggacttgc ggctggagct gcccaagact 26760
 actcaaccg aataaactac atgagcgagg gacccacat gatatcccg gtcaacggaa 26820
 tacgccccca ccgaaacga attctcctgg aacaggcggc tattaccacc acacctcgt 26880
 ataacctta tccccgtagt tggcccgctg cctgggtga ccaggaaagt ccgctccca 26940
 ccactgtgtt acttccaga gacgccagg ccgaagtca gatgactaac tcaggggcgc 27000
 agcttgcggg cggctttcgt cacagggtgc ggtcgcccg gcagggtata actcaactga 27060
 caatcagagg gcgaggtatt cagctcaacg acgagtcggg gagctcctc ctggctctc 27120
 gtccggagg gacatttcag atcgcgagg ccggccgctc ttattcacg cctcgtcagg 27180
 caatcctaac tctcagacc tctcctctg agcccgctc tggaggcatt ggaactctg 27240
 aattttatga ggagtgtg ccacgggtc actttaacc ctctcggga cctcccgcc 27300
 actatccgga tcaattatt cctaacttg acgcggtaaa ggactcggc gacggctacg 27360
 actgaatgtt ataagttct gtccatccg acccactat tcatgtgtg tgcagatga 27420
 gcgcgcaaga ccgtctgaag atacctcaa ccccggtat ccatatgaca ccgaaaccg 27480
 tctccaact gtgcctttt ttactctcc cttgtatc ccaatgggt ttcaagagag 27540
 tccccctgg gtactctct tgcgctatc cgaacctca gttacctca atggcatgct 27600
 tgcgtcaaaa atgggcaacg gcctctctc ggacgaggc ggcaacctta cctccaaaa 27660
 tgaaccact gtgagccac ctctcaaaa aaccaagta aacataaac tggaaatct 27720
 tgaacccct acagttaact cagaagcct aactgtggc ggcggcac ctctaatgt 27780
 cgcggcaac acactcaac tgaatcaca ggcccgcta accgtgacg actcaaac 27840
 tagcattgc acccaaggac cctcacagt gtcagaagga aagctagccc tgcaaacatc 27900
 aggcctctc accaaccg atagcagtag ccttactat actgctcac cccctcaac 27960
 tactgccact gtagcttg gcattgact gaaagagccc atttatcac aaaatggaa 28020
 actaggcta aagtacggg ctcttttga tgaacagac gacctaaaca cttgacct 28080
 agcaactgt ccaggttga ctattaata tacttcttg caaactaaag ttactggagc 28140
 ctgggtttt gattcacaag gcaatatga actaatga gcaggaggac taaggattga 28200
 ttctcaaaa agacgccta tactgatgt tagttatccg ttgatgctc aaaaccaact 28260
 aatctaaga ctaggacag gccctcttt tataaactca gcccaact tggatattaa 28320
 ctacaacaaa ggcccttact tgtttacag tcaaaat tcaaaaagc ttgaggttaa 28380
 cctaagcact gccagggtg tgaatttga cgctacagc atagccatta atgcaggaga 28440
 tgggcttga tttggtcac ctatgcac aaacacaaat cccctcaaa caaaattgg 28500
 ccattggcta gaatttgat caacaaggc tatgttct aaactaggaa ctggccttag 28560
 tttgacagc acaggtgcca ttacagtag aaacaaaat atgataagc taactttgt 28620
 gaccaccca gctccatct ctaactgtg actaatga gagaagatg ctaaactcac 28680
 tttgtctta acaaatgtg gcagtcaat acttgctca gttcagttt tggctgttaa 28740
 aggcagttt gctccaat ctggaacagt tcaagtgt catctatta taagattga 28800
 cgaaaatgga gtgctacta acaattcct cctggacca gaatttga actttagaa 28860
 tggagatct actgaaggc cagcctatc aaacgctgt ggatttatgc ctacactatc 28920
 agcttatcca aatctcac gtaaaactg caaaagtaac attgcagtc aagtttact 28980
 aaacggagac aaaactaac ctgtaacat aaccattaca ctaaacgga cacaggaaac 29040
 aggagacaca actccaagt catactctat gtcattttca tgggactgt ctggccaca 29100
 ctacattaat gaaatttt ccacatctc ttactttt tcatattg ccaagaata 29160
 aagaatggt tgtgtatgt ttcaacgtg ttattttca attgcagaaa attcaagtc 29220
 attttcatt cagtagtata gcccaccac cacatagctt atacagatca ccgtacctta 29280

atcaaaactca cagaacccta gtattcaacc tgccacctcc ctccaacac acagagtaca 29340
 cagtcttttc tccccggctg gccttaaaaa gcatcatatc atgggtaaca gacatattct 29400
 taggtgttat attccacacg gtttctgtc gagccaaacg ctcatcagtg atattaataa 29460
 actccccggg cagctcactt aagttcatgt cgctgtccag ctgctgagcc acaggctgct 29520
 gtccaacttg cggttgctta acgggcgcg aaggagaagt ccacgcctac atgggggtag 29580
 agtcataatc gtgcatcagg ataggcggtt ggtgctgcag cagcgcgcga ataaactgct 29640
 gccgcccggg ctccgtcctg caggaatata acatggcagt ggtctctca gcatgattc 29700
 gcaccgcccg cagcataagg cgcttgtcc tccgggcaca gcagcgcacc ctgatctcac 29760
 taaatcagc acagtaactg cagcacagca ccacaatatt gttcaaatc ccacagtga 29820
 aggcgctgta tcaaagctc atggcgggga ccacagaacc cagtgggca tcataccaca 29880
 agcgcaggta gattaagtgg cgacctca taaacagct ggacataaac attacctctt 29940
 ttggcatgtt gtaattcacc acctccgggt accatataa cctctgatta aacatggcgc 30000
 catccaccac catcctaacc cagctggcca aaacctgccc gccggctata cactgcaggg 30060
 aaccgggact ggaacaatga cagtggagag cccaggactc gtaacatgg atcatcatgc 30120
 tcgtcatgat atcaatgttg gcacaacaca ggacacagtg cataacttc ctaggatta 30180
 caagctctc ccggttaga accatatccc aggaacaac ccattctga atcagcgtaa 30240
 atcccacat gcagggaaga cctgcacgt aactcacgtt gtgcattgtc aaagtgttac 30300
 attcgggcag cagcggatga tctccagta tggtagcgcg ggtttctgtc tcaaaaggag 30360
 gtagacgac octactgtac ggagtgcgc gagacaacc agatcgtgtt ggtcgtagt 30420
 tcatgcaaaa tggaaacggg gacgtagtca ttttctga agcaaaacca ggtgcggg 30480
 tgacaaacag atctgcgtc ccggtctgc cgcttagatc gctctgtga gtagtttag 30540
 tatatcact ctctcaaac atocagggc cccctggctt cgggttctat gtaactct 30600
 tcatgcccg ctgcctgat aacatccacc accgcagaat aagccacac cagccaacct 30660
 acacattgt tctgcagtc acacacggga ggagcgggaa gactggag aacctgtt 30720
 tttttttat tcaaaagt tatocaaa ctcaaatga agatctatta agtgaacgg 30780
 ctccctccg gtggcgtgtt caaactctac agccaagaa cagataatgg cattgttag 30840
 atgttgaca atggcttoca aaaggcaaac ggccctcag tocaagtga cgtaaaggct 30900
 aaacccctca ggggtgaatct cctctataa cattocagca tctcaacca tgcccaata 30960
 attctatct cgcaccttc tcaatatat tcaagcaaa tccgaatat taagtcggc 31020
 cattgtaaaa atctgtcca gagcgcctc cacttcagc ctcaagcagc gaatcatgat 31080
 tgcaaaaatt caggttctc acagacctgt ataagattca aaagcggaa attacaata 31140
 ataccgcgat ccgtaggtc ccttcgagg gccagctgaa cataatcgt caggtctgca 31200
 cggaccagc cggccactc cccgccagga accatgaca aagaaccac actgattatg 31260
 acacgcatac tcggagctat gtaaccagc gtagccccga tgtaagctt tgcatggg 31320
 ggcatataa aatgcaaggt gctgctcaa aatcaggca aagcctcgc caaaaaagaa 31380
 agcacatcgt agtcatgctc atgcagataa aggcaggtaa gctccggaac caccacagaa 31440
 aaagacacca ttttctctc aaacatgtc gcgggttct gcataaacac aaaataaat 31500
 aacaaaaaa catttaaca ttagaagct gtcttacaac aggaaaaaa acccttataa 31560
 gcataagacg gactacggc atgccggcg gaccgtaaaa aaactggta ccgtgattaa 31620
 aaagcaccac cgacagctc tcggtcatgt ccggagtc atgtgaagac tcggtaaaca 31680
 catcagggtt attcatatc gtacgtgcta aaaagcgacc gaaatagccc gggggaatac 31740
 ataccgcag gcgtagagac aacattacag ccccatagg aggtataaca aaattaatag 31800
 gagagaaaa cacataaaca cctgaaaaa cctcctgctt aggcataata gcacctccc 31860
 gctccagaac aacatacagc gctccacag cggcagccat aacagtcagc ctaccagta 31920
 aaaaagaaaa cctattaaaa aaacaccat cgacacggca ccagtcacat cagtcacagt 31980
 gtaaaaaagg gccaagtga gagcgagt atataggact aaaaatgac gtaacggta 32040
 aagttccaaa aaacaccca gaaaaccga cgcgaacct cgcacagaaa cgaagccaa 32100
 aaacccaca acttctcaa atcgtcactt ccgtttccc acgtacgct acttccatt 32160
 ttaagaaaac tacaattccc aacacataa agttactcc ccctaaacc tacgtaccc 32220
 gcccggttc cagccccgc gccacgtcac aaatccacc cctcattat catattggct 32280

tcaatccaaa ataaggatata ttattgatga tgttacatcg ttaattaacg atttcgaacc 32340
 cgggggtaccg aattcctcga gtctagagga gcatgcgacg tcgcaattcg ccctatagtg 32400
 agtcgtatta caattcactg gccgtcgttt tacaacgtcg tgactgggaa aacctggcg 32460
 ttaccaact taatcgctt gcagcacatc ccccttcgc cagctggcgt aatagcgaag 32520
 agggccgcac cgatcgccct tccaacagt tgcgcagcct gaatggcgaa tggaaattgt 32580
 aagcgttaat attttgttaa aattcgcgtt aaattttgt taaatcagct catttttaa 32640
 ccaataggcc gaaatcggca aaatccctta taaatcaaaa gaatagaccg agatagggtt 32700
 gagtgttgtt ccagtttggga acaagagtc actattaaag aacgtggact ccaacgtcaa 32760
 agggcgaaaa accgtctatc agggcgatgg cccactacgt gaaccatcac cctaatcaag 32820
 tttttgggg tcgaggtgcc gtaaagcact aaatcggaac cctaaaggga gccccgatt 32880
 tagagcttga cggggaaagc cggcgaaagt ggcgagaaag gaagggaaga aagcgaagg 32940
 agcgggcgtt agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacaccgc 33000
 cgcgcttaat gcgccctac agggcgctgc ctgatcggtt attttctct tacgcatctg 33060
 tgcggtattt cacaccgat acaggtggca ctttcgggg aaatgtgcgc ggaaccccta 33120
 ttgtttatt ttctaaata cattcaata tctatccgt catgagaca taacctgat 33180
 aatgtctca ataattga aaaaggaga gtatgagat tcaacattc cgtgtcgccc 33240
 ttattccctt ttttgcgca tttgccttc ctgttttgc taccagaa acgctggtga 33300
 aagtaaaaga tgcgaagat cagttgggtg cagcagtggtt ttatcga ctggatctca 33360
 acagcgtaa gatccttgag agttttcgcc ccgaagaacg ttttcaatg atgagcattt 33420
 ttaaagtct gctatgtggc gcggtattat ccgtattga cgcgggca gagcaactg 33480
 gtgcgcgat acactattct cagaatgact tggttgagta ctaccagtc acagaaaagc 33540
 atcttacgga tggcatgaca gtaagagaat tatgcagtgc tgocataacc atgagtata 33600
 acatgcggc caacttact ctgacaacga tggaggac gaaggagcta accgtttt 33660
 tgcacaacat gggggatcat gtaactcgc ttgatcttg ggaacggag ctgaatgaag 33720
 ccatccaaa cgcagagcgt gacaccga tgcctgtagc aatggcaaca acgttgcga 33780
 aactattaac tggcgaacta ctactctag ctcccgca acaataata gactggtg 33840
 aggcggataa agttgcagga ccactctgc gctcggcctt tccgctggc tggttattg 33900
 ctgataaatc tggagccgtt gagcgtgggt ctgcgggtat cattgcagca ctggggccag 33960
 atggtaagc ctccgtatc gtagttatct acacgacggg gactcaggca actatggatg 34020
 aacgaatag acagatcgtt gagataggtt cctcactgat taagcattgg taactgtcag 34080
 accaagtta ctcatatata ctttagattg atttaaaact tcatttttaa tttaaaagga 34140
 tctaggtgaa gatccctttt gataatctca tgacaaaat cccttaacgt gagttttcgt 34200
 tccactgagc gtcagacccc gtagaaaaga tcaaggatc ttcttgagat ctttttttc 34260
 tgcgcgtaat ctgctgctt cacaacaaa aaccaccgt accagcgggt gtttgttgc 34320
 cggatcaaga gctaccaact cttttccga aggtactgg ctacagca gcgcagatac 34380
 caaatactgt tcttctagt tagccgtagt taggccacca ctcaagaac tctgtagcac 34440
 cgcctacata cctcgtctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt 34500
 cgtgtcttac cgggttggac tcaagacgat agttaccgga taaggcgag cgtcgggt 34560
 gaacgggggg ttcgtgcaca cagcccagct tggagcgaac gacctacacc gaactgagat 34620
 acctacagcg tgagctatga gaaagcgcca cgcttccga agggagaaag gcggacaggt 34680
 atccggttaag cggcaggggtc ggaacaggag agcgacagag ggagcttca ggggaaacg 34740
 cctggtatct ttatagtcct gtcgggttc gccacctctg actgagcgt cgattttgt 34800
 gatgctcgtc agggggggcg agcctatgga aaaacggcag caacggcgcc ttttacgtt 34860
 tcttggcctt ttctggcct tttgtcaca tgttcttcc tgcgtatcc cctgattctg 34920
 tggataaccg tattaccgcc ttgagttag ctgataccgc tcggcgagc cgaacgaccg 34980
 agcgacgca gtcagttagc gaggaagcgg aagagcgccc aatacgcaa cgcctctcc 35040
 ccgcgcttg gccgattcat taatgcagct ggcacgacag gtttccgac tggaaagcg 35100
 gcagttagcg caacgaatt aatgtgagtt agctcactca ttaggcaccc caggctttac 35160
 actttatct tccggctcgt atgttgtgtg gaattgtgag cggataaaa tttcacag 35220
 gaaacagcta tgacctgat tacgcaagc tatttaggtg acatataga atactcaagc 35280

tagttaatta acgttaatta acatcatcaa taatatacct tatTTTggat tgaagccaat 35340
atgataatga ggggggtggag ttgtgacgt ggCGCGgggc gTgggaacgg ggcgggtgac 35400
gtagtagtgt ggcggaagtg tgatgttgca agtgtggcgg aacacatgta agcgacggat 35460
gtggcaaaag tgacgtttt ggtgtgcgcc ggtgtacaca ggaagtgaca attttcgcgc 35520
ggttttaggc ggatgttgta gtaaatttgg gcgtaaccga gtaagatttg gccattttcg 35580
cgggaaaact gaataagagg aagtgaatc tgaataattt tgtgttactc atagcgcgta 35640
atctctagca t 35651

<212> Type : DNA

<211> Length : 35651

SequenceName : SEQ ID No.1

SequenceDescription :

Custom Codon

• Sequence Name : SEQ ID No.1

REFERENCES

1. Andersen, M. M. and T. Ronne. 1991. Side-effects with Japanese encephalitis vaccine. *Lancet* 337:1044.
2. Ashok, M. S. and P. N. Rangarajan. 2000. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies. *Vaccine* 18:68-75.
3. Both, G. W., L. J. Lockett, V. Janardhana, S. J. Edwards, A. R. Bellamy, F. L. Graham, L. Prevec, and M. E. Andrew. 1993. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. *Virology* 193:940-950.
4. Casimiro, D. R., A. Tang, L. Chen, T. M. Fu, R. K. Evans, M. E. Davies, D. C. Freed, W. Hurni, J. M. Aste-Amezaga, L. Guan, R. Long, L. Huang, V. Harris, D. K. Nawrocki, H. Mach, R. D. Troutman, L. A. Isopi, K. K. Murthy, K. Rice, K. A. Wilson, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol.* 77:7663-7668.
5. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression and replication. *Annu. Rev. Microbiol.* 44:649.
6. Chang, G.-J. J., A. R. Hunt, and B. Davis. 2000. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. *Journal of Virology* 74:4244-4252.
7. Chen, H. W., C. H. Pan, M. Y. Liao, R. Jou, C. J. Tsai, H. J. Wu, Y. L. Lin, and M. H. Tao. 1999. Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. *J. Virol.* 73:10137-10145.
8. Chengalvala, M. V., B. M. Bhat, R. A. Bhat, S. K. Dheer, M. D. Lubeck, R. H. Purcell, and K. K. Murthy. 1997. Replication and immunogenicity of Ad7-,

- Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. *Vaccine* 15:335-339.
9. **Flanagan, B., C. R. Pringle, and K. N. Leppard.** 1997. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. *J Gen. Virol.* 78 (Pt 5):991-997.
10. **Fonseca, B. A., S. Pincus, R. E. Shope, E. Paoletti, and P. W. Mason.** 1994. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. *Vaccine* 12:279-285.
11. **Fooks, A. R., D. Jeevarajah, J. Lee, A. Warnes, S. Niewiesk, M. ter, V, J. R. Stephenson, and J. C. Clegg.** 1998. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. *J Gen. Virol.* 79 (Pt 5):1027-1031.
12. **Guirakhoo, F., R. Weltzin, T. J. Chambers, Z. X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath.** 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. *J Virol.* 74:5477-5485.
13. **Imler J.L.** 1995. Adenovirus vectors as recombinant viral vaccines. *Vaccine* 13:1143-1151.
14. **Jan, L. R., C. S. Yang, L. S. Henchal, H. Sumiyoshi, P. L. Summers, D. R. Dubois, and C. J. Lai.** 1993. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein. *Am. J Trop. Med. Hyg.* 48:412-423.
15. **Kaur, R., G. Sachdeva, and S. Vрати.** 2002. Plasmid DNA immunization against Japanese Encephalitis Virus: immunogenicity of membrane-anchored and secretory envelope protein. *J. Infect. Dis.* 185:1-12.
16. **Kaur, R. and S. Vрати.** 2003. Development of a recombinant vaccine against Japanese encephalitis. *J Neurovirol* 9:421-431.
17. **Kimura-Kiroda, J. and K. Yasui.** 1988. Protection of mice against Japanese encephalitis virus by passive administration of monoclonal antibodies. *J. Immunol.* 141:3606-3610.
18. **Konishi, E., S. Pincus, E. Paoletti, R. E. Shope, T. Burrage, and P. W. Mason.** 1992. Mice immunized with a subviral particle containing the Japanese

encephalitis virus prM/M and E proteins are protected from lethal JEV infection. *Virology* 188:714-720.

19. **Konishi, E., M. Yamaoka, S. W. Khin, I. Kurane, K. Takada, and P. W. Mason.** 1999. The anamnestic neutralizing antibody response is critical for
5 protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. *J. Virol.* 73:5527-5534.
20. **Konishi, E., M. Yamaoka, Khin-Sane-Win, I. Kurane, and Mason P.W.** 1998. Induction of protective immunity against Japanese encephalitis in mice by
10 immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. *Journal of Virology* 72:4925-4930.
21. **Lemiale, F., W. P. Kong, L. M. Akyurek, X. Ling, Y. Huang, B. K. Chakrabarti, M. Eckhaus, and G. J. Nabel.** 2003. Enhanced mucosal
15 immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. *J Virol.* 77:10078-10087.
22. **Lin, B., C. R. Parrish, J. M. Murray, and P. J. Wright.** 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. *Virology* 202:885-890.
- 20 23. **Livingston, P. G., I. Kurane, C. J. Lai, M. Bray, and F. A. Ennis.** 1994. Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones. *J Virol.* 68:3283-3288.
24. **Lubeck, M. D., A. R. Davis, M. Chengalvala, R. J. Natuk, J. E. Morin, K. Molnar-Kimber, B. B. Mason, B. M. Bhat, S. Mizutani, P. P. Hung, and .**
25 1989. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. *Proc. Natl. Acad. Sci. U. S. A* 86:6763-6767.
25. **Mason P.W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti.** 1991. Japanese encephalitis virus-Vaccinia recombinants produce
30 particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. *Virology* 180:294-305.
26. **McMinn, P. C.** 1997. The molecular basis of virulence of the encephalitogenic flaviviruses. *J Gen. Virol.* 78 (Pt 11):2711-2722.

27. **Men, R., M. Bray, and C.-J. Lai.** 1991. Carboxy-terminal truncated dengue virus envelope glycoprotein expressed on the cell surface and secreted intracellularly exhibit increased immunogenicity in mice. *Journal of Virology* 65:1400-1407.
- 5 28. **Monath, T. P.** 2001. Prospects for development of a vaccine against the West Nile virus. *Ann. N. Y. Acad. Sci.* 951:1-12.
29. **Monath, T. P.** 2002. Japanese encephalitis vaccines: current vaccines and future prospects. *Curr. Top. Microbiol. Immunol.* 267:105-138.
- 10 30. **Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo.** 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. *Vaccine* 20:1004-1018.
- 15 31. **Monath, T. P., K. Soike, I. Levenbook, Z. X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo.** 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. *Vaccine* 17:1869-1882.
- 20 32. **Pan, C. H., H. W. Chen, H. W. Huang, and M. H. Tao.** 2001. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. *J Virol.* 75:11457-11463.
33. **Plesner, A. M. and T. Ronne.** 1997. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. *Vaccine* 15:1239-1243.
- 25 34. **Putnak, R., R. Feighny, J. Burrous, M. Cochran, C. Hackett, G. Smith, and C. Hoke.** 1991. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. *Am. J Trop. Med. Hyg.* 45:159-167.
- 30 35. **Raikwar, S. P., P. Malik, O. Singh, and S. Vрати.** 1997. Recombinant adenovirus synthesizing cell surface-anchored beta hCG induces bionutralizing antibodies in rats. *Gene* 190:197-202.
36. **Ramakrishna, C., A. Desai, S. K. Shankar, A. Chandramuki, and V. Ravi.** 1999. Oral immunisation of mice with live Japanese encephalitis virus induces a protective immune response. *Vaccine* 17:3102-3108.

37. **Raviprakash, K., T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, C. G. Hayes, and K. R. Porter.** 2000. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. *Vaccine* 18:2426-2434.
- 5 38. **Ruff, T. A., D. Eisen, A. Fuller, and R. Kas.** 1991. Adverse reactions to Japanese encephalitis vaccine. *Lancet* 338:881-882.
39. **Sakaguchi, M., M. Yoshida, W. Kuroda, O. Harayama, Y. Matsunaga, and S. Inouye.** 2000. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. *Vaccine* 15:121-122.
- 10 40. **Sharpe, S., A. Fooks, J. Lee, K. Hayes, C. Clegg, and M. Cranage.** 2002. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. *Virology* 293:210-216.
41. **Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans,**
15 **Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman,**
20 **L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini.** 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. *Nature* 415:331-335.
- 25 42. **Vos, A., A. Neubert, E. Pommerening, T. Muller, L. Dohner, L. Neubert, and K. Hughes.** 2001. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. *J Gen. Virol.* 82:2191-2197.
43. **Vrati, S., V. Agarwal, P. Malik, S. A. Wani, and M. Saini.** 1999. Molecular
30 characterization of an Indian isolate of Japanese encephalitis virus that shows an extended lag phase during growth. *J. Gen. Virol.* 80:1665-1671.

44. **Vrati, S., R. K. Giri, A. Razdan, and P. Malik.** 1999. Complete nucleotide sequence of an Indian strain of Japanese encephalitis virus: sequence comparison with other strains and phylogenetic analysis. *Am. J. Trop. Med. Hyg.* **61**:677-680.
45. **World Health Organization.** 1998. Japanese encephalitis vaccines. *Wkly Epidemiol Rec* **73**:334-344.
46. **Xiang, Z., Y. Li, G. Gao, J. M. Wilson, and H. C. Ertl.** 2003. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. *J Immunol.* **171**:4287-4293.
47. **Xiang, Z. Q., G. P. Gao, A. Reyes-Sandoval, Y. Li, J. M. Wilson, and H. C. Ertl.** 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. *J Virol.* **77**:10780-10789.
48. **Xiang, Z. Q., Y. Yang, J. M. Wilson, and H. C. Ertl.** 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. *Virology* **219**:220-227.
49. **Yoshida, T., K. Okuda, K. Q. Xin, K. Tadokoro, J. Fukushima, S. Toda, E. Hagiwara, K. Hamajima, T. Koshino, and T. Salto.** 2001. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. *Clin. Exp. Immunol.* **124**:445-452.
50. **Zhao, J., Y. Lou, J. Pinczewski, N. Malkevitch, K. Aldrich, V. S. Kalyanaraman, D. Venzon, B. Peng, L. J. Patterson, Y. Edghill-Smith, R. Woodward, G. N. Pavlakis, and M. Robert-Guroff.** 2003. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. *Vaccine* **21**:4022-4035.